

## TABLE OF CONTENTS

### *Poster Session I* *Polydrug Abuse*

<b>Spanish Version of the ARCI (49-Item Short Form): Response Patterns Under Different Drug Conditions</b> J. Cami, X. Lamas, M. T. Teran and M. Farre.....	1
<b>Standard Spanish Version of the Addiction Research Center Inventory (ARCI) in a U. S. Hispanic Population</b> D. J. Guyen, E. G. Singleton, and J. E. Henningfield .....	2
<b>A Cross-Validation of the Addiction Research Center Drug Expectancy Questionnaire (ARCDEQ)</b> C. J. Wong, D. B. Newlin, and E. G. Singleton.....	3
<b>Measuring Drug-Induced Behavioral Impairment: Construct Validity</b> R. C. Taylor, S. J. Heishman, and E. G. Singleton.....	4
<b>Measuring Drug-Induced Behavioral Impairment: Criterion-Related Validity</b> S. J. Heishman, E. G. Singleton, J. M. Lutz, and J. E. Henningfield.....	5
<b>Drugs As Conditioned Reinforcers in Humans</b> A. J. Mattox, C. R. Schuster, and C. E. Johanson .....	6
<b>Card Sorting: A Method to Evaluate Performance Effects of Abused Drugs</b> M. Butchsky, J. Nichels, N. Snidow, and W. B. Pickworth .....	7
<b>Cognitive Function in Dually-Dependent Opiate and Cocaine Users Before and After Buprenorphine or Placebo Treatment: An N400 ERP Study</b> E. M. Kouri, S. E. Lukas, and J. H. Mendelson .....	8
<b>Long-Term Effects of Buprenorphine for Treatment of Combined Heroin and Cocaine Dependence</b> D. R. Gastfriend, J. H. Mendelson, N. K. Mello, S. K. Teoh, S. Reif, S. L. Baker.....	9
<b>A Contingency Management Procedure for Opioid/Cocaine Abstinence in Methadone-Maintained Cocaine Abusers: A Pilot Study</b> A. H. Oliveto, R. Schottenfeld, T. R. Kosten, and J. Falcioni .....	10
<b>Effects of Pre-treatment of Diazepam on Methadone Self-Administration</b> R. Spiga, S. Rafieha, J. Grabowski, P. B. Silverman, and R. A. Meisch .....	11
<b>Time Course of Cocaine Withdrawal Symptoms in Cocaine-Abusing Methadone-Maintained Patients</b> A. Margolin, S. K. Avants, and T. R. Kosten.....	12

<b>Clinical Use of Buspirone in Cocaine-Dependent HIV-Infected Patients in MMT</b>	
M. D. Herbst, N. Nanda, and S. L. Batki .....	13
<b>Acupuncture for the Treatment of Cocaine Abuse in HIV-Positive Methadone-Maintained Patients</b>	
S. K. Avants, A. Margolin, P. Chang, and T. R. Kosten.....	14
<b>A Comparison of Cocaine-Dependent Patients With and Without A Co-existing Opioid Use Disorder</b>	
R. D. Weiss, J. Martinez-Raga, M. L. Griffin, and C. Hufford.....	15
<b>Pattern of Cocaine Use in Methadone-Maintained Individuals</b>	
F. R. Levin, R. W. Foltin, and M. W. Fischman .....	16
<b>Cocaine Abuse is Decreased With Effective Methadone Maintenance Treatment at an Urban Department of Veterans Affairs (DVA) Program</b>	
L. Borg, D. M. Broe, A. Ho, and M. J. Kreek.....	17
<b>Nicotine and Cocaine Dynamics: Patterns and Consequences.</b>	
M. E. Khalsa, M. D. Anglin, and F. H. Gawin.....	18
<b>Relationship of Psychopathology to Cocaine Versus Cocaine and Alcohol Abuse</b>	
R. C. McMahon, R. M. Malow, and S. J. Ireland.....	19
<b>Alcohol and Cocaine Interactions in Humans: Hormonal and Pharmacokinetic Profile</b>	
M. Farre, R. de la Torre, M. T. Teran, M. L. Gonzalez, E. Menoya, J. Ortuno, P. N. Roset, J. Segura, and J. Camf.....	20
<b>Neuropsychological Recovery in Alcoholics and Cocaine Users</b>	
M. J. Selby, M. Quiroga, S. J. Ireland, R. M. Malow, and R. L. Azrin.....	21
<b>Treatment Intensity Predicts Abstinence and Reduction in Drug Use for Cocaine-Dependent Methadone Patients</b>	
S. Magura, A. Rosenblum, M. Palij, M. Lovejoy, J. Foote, L. Handelsman, and B. Stimmel.....	22
<b>Retention in High Intensity Treatment for Cocaine Use</b>	
A. Rosenblum, S. Magura, M. Palij, M. Lovejoy, J. Foote, L. Handelsman, and B. Stimmel.....	23
<b>Social Identities and Treatment Outcomes Among Alcohol and Cocaine Users in Private Treatment</b>	
C. Weisz.....	24
<b>Effects of Desipramine, Amantadine, or Fluoxetine on Cocaine and Opioid Use in Buprenorphine-Maintained Patients: A Pilot Study</b>	
A. Oliveto, T. R. Kosten, R. Schottenfeld, and D. Ziedonis.....	25
<b>Drug Treatment Delivery: Staffing Pattern, Service Provision and Perception of Quality</b>	
M. L. Polinsky and Y. I. Hser .....	26

<b>Organizational Factors Related to the Differential Provision of Services in 17 Drug Treatment Programs</b>	
T. A. Hagan, J. C. Ball, A. T. McLellan, K. Meyers, and M. Randall .....	27
<b>Drug Treatment Program and Client Retention: A Hierarchical Linear Model</b>	
C. -P. Chou and Y. -I. Hser .....	28
<b>Measuring Participation in Outpatient Drug Treatment</b>	
J. M. Hawke.....	29
<b>Referring Legally Mandated Clients to Drug Abuse Treatment Programs: The New York City Experience</b>	
M. Natarajan and G. P. Falkin.....	30
<b>MMPI-2 Psychopathology in Addicted Women Reporting Childhood Sexual Abuse</b>	
S. B. Barker, J. S. Knisely, K. S. Ingersoll, and D. L. Haller.....	31
<b>Antepartum Hepatitis B Vaccination in High Risk Patients: Is it Feasible?</b>	
M. J. Dinsmoor, E. R. Spear, M. E. Willis, and M. R. Escobar .....	32
<b>Perinatal Addicted Women: Effects of Hostility on Relapse Rates in Short-Term Outpatient Treatment</b>	
C. W. Motley, J. S. Knisely, and S. Schnoll.....	33
<b>Anger Management in Substance Abuse Treatment Patients</b>	
P. M. Reilly, H. W. Clark, M. S. Shopshire, D. J. Sorenson, and E. W. Lewis .....	34
<i>Substance Abuse and Psychiatric Problems</i>	
<b>Validity of the SCID in Substance Abuse Patients</b>	
H. Kranzler, B. Rounsaville, and H. Tennen.....	35
<b>Impact of Substance Abuse on the Diagnosis of Axis II Disorders</b>	
A. Apter, H. Kranzler, V. Klinghoffer, and B. Rounsaville.....	36
<b>Diagnosing Mental Disorders in Substance Abusers: Test-Retest Reliability of Two Interviews</b>	
H. E. Ross, R. Swinson, S. Doumani, and E. Larkin .....	37
<b>Modified Therapeutic Community for Homeless MICAS Profiles</b>	
S. Sacks and K. Foster, Sr. ....	38
<b>Community Based Treatment Programs for MICAS: A Typology of Different Treatment Environments</b>	
J. Collins, J. J. Rivera, and M. Rahav.....	39
<b>Correlates of Treatment Retention for MICAS: A Report on a New Drop-out Measurement Instrument</b>	
M. Rahav, L. Nuttbrock, J. J. Rivera, and D. Ng-Mak.....	40

<b>Comorbidity Among Adolescents in Therapeutic Community Treatment</b>	
N. Jainchill, G. Bhattacharya, and J. Yagelka.....	41
<b>The Reliability of the ASI Among Clients With Severe Mental Illness and Substance Abuse Problems</b>	
D. Zanis, A. T. McLellan, M. Burke, and M. Randall.....	42
<b>Client Treatment Needs Assessment Instrument</b>	
Y. I. Hser and M. L. Polinsky.....	43
<b>Depression in Drug and Alcohol Dependency</b>	
A. Eriksen, N. S. Miller, M. S. Gold, and N. G. Hoffman.....	44
<b>Analyses of Depression and Addiction Severity Controlling for Social Support</b>	
M. Chan, J. Guydish, B. Tajima, and D. Werdegard .....	45
<b>Outcomes for Drug Users in a Day Treatment Program</b>	
J. Guydish, A. Razban, A. Acampora, and D. Werdegard.....	46
<b>Psychiatric Comorbidity in Cocaine Addiction</b>	
D. B. Marlowe, S. D. Husband, R. J. Lamb, K. C. Kirby, M. Y. Iguchi, and J. J. Platt.....	47
<b>The Importance of Evaluating Early Onset Anxiety Disorders in a Cocaine Dependent Population: A Replication</b>	
D. B. Dewart, R. A. Roemer, P. Jackson, and J. Cornwell.....	48
<b>Early Decline in Self-Reported Dysphoria in Inner-City Cocaine Addicts Beginning Treatment</b>	
M. Y. Iguchi, S. D. Husband, D. B. Marlowe, K. C. Kirby, R. J. Lamb, and J. J. Platt.....	49
 <b><i>HIV/AIDS</i></b>	
<b>HIV Risk Behaviors in Perinatal and Inpatient Drug Addicts</b>	
K. S. Ingersoll, D. L. Haller, and K. S. Dawson.....	50
<b>Psychosocial Correlates of HIV Risk Among Pregnant Drug Abusers</b>	
R. M. Malow, S. J. Ireland, M. Quiroga, and F. J. Penedo.....	51
<b>HIV Risk and Drug Use Among College Women</b>	
M. Leik, R. Malow, S. Ireland, L. Porter, and J. Lewis.....	52
<b>AIDS-Related Risk Factors Among Southern College Students</b>	
E. J. Brown .....	53
<b>A Test of the AIDS Risk Reduction Model With Indigent, Cocaine Abusing Women</b>	
S. J. Ireland, R. M. Malow, L. Alberga, F. Penedo, and J. Lewis .....	54

<b>Opiate Dependence, Gambling and HIV Risk in a Low Income Population</b>	
L. Roehrich, J. L. Sorenson, and P. Good.....	55
<b>Antisocial Personality Disorder and Aids Related Risk Behaviors</b>	
J. J. Rivera, M. Rahav, and L. Nuttbrock.....	56
<b>Attitudes and Perceptions Regarding the Risk of AIDS Among Mentally III, Chemical Abusing, Homeless Men</b>	
L. Nuttbrock, M. Rahav, and J. J. Rivera.....	57
<b>Drug Use and HIV-Risk Behavior Among Non-injecting Female Sex Partners of Injecting Drug Users in Newark and Jersey City, New Jersey</b>	
V. Lidz, M. Y. Iguchi, J. F. French, and J. J. Platt .....	58
<b>The AIDS Risk Reduction Model and Condom Use Among Injection Drug Users</b>	
M. R. Kowalewski, J. A. Stein, D. Longshore, and M. D. Anglin .....	59
<b>Recent Sexual Activity and Condom Use in Opioid Drug Abusers Entering Methadone Maintenance Treatment</b>	
V. L. King, R. K. Brooner, M. Kidorf, and G. W. Bigelow.....	60
<b>RNA: Risk Network Assessment for Epidemiologic Research on Drug Abuse and HIV</b>	
D. Taylor, R. K. Price, D. Mager, and L. B. Cottler .....	61
<b>Cocaine and Crack Use Among High-Risk Addicts in an Enhanced Methadone Maintenance Program</b>	
M. D. Anglin, C. E. Grella, and S. E. Wugalter.....	62
<b>Cocaine Use and HIV Infection in Methadone Maintained and Untreated Intravenous Drug Users</b>	
B. Meandzija, P. O'Connor, B. Fitzgerald, B. Rounsaville, and T. Kosten .....	63
<b>Validity of Self-Report Data on Risk Behaviors from Heroin Addicts Entering Free Methadone Treatment</b>	
C. E. Grella, S. Chaiken, and M. D. Anglin .....	64
<b>An Automated Version of the Risk Assessment Battery (RAB): Reliability, Validity, and Subject Acceptance</b>	
E. C. Snider, H. A. Navaline, C. J. Petro, D. J. Tobin, D. Metzger, A. I. Alterman, and G. E. Woody.....	65
<b>Factors Associated With Unsafe Needle Injection in Denver</b>	
R. E. Booth and S. K. Koester.....	66
<b>Training in Interpersonal Problem-Solving for Injection Drug Users: AIDS Education and HIV-Risk Reduction</b>	
J. J. Platt, M. Y. Iguchi, V. Lidz, and D. Mathis.....	67
<b>Indirect Sharing: Injection-Associated HIV Risks</b>	
S. K. Koester and R. E. Booth.....	68

<b>Are Drug Treatment Providers Willing to Participate in Harm Reduction and to What Extent?</b>	
P. E. Evans, H. W. Clark, G. Hughes, C. Hoyo, K. Robinson, M. Lodico, D. DePhilippis, and M. Shopshire .....	69
<b>One Year Retention in Methadone Maintenance and HIV Risk Behavior</b>	
E. A. Wells, D. A. Calsyn, A. J. Saxon, T. R. Jackson and L. L. Clark.....	70
<b>Risk for HIV Infection in Drug Users Refusing Confidential HIV Testing</b>	
A. Umbricht-Schneider, D. H. Ginn, K. M. Pabst, and G. E. Bigelow.....	71
<b>Violent and Other Deaths Among St. Louis Substance Users at High Risk for HIV</b>	
M. Bidaut-Russell, L. B. Cottler, and W. M. Compton .....	72
<b>Community-Based HIV Interventions to Drug-Using Women</b>	
C. J. Reback and V. B. Brown.....	73
<b>Comparison of HIV Seroprevalence Between IV Cocaine and Heroin Users</b>	
B. A. Beall, D. L. Frankenfield, C. S. Contoreggi, and W. R. Lange.....	74
<b>Western Blot Confirmation of Urine Screens for HIV</b>	
B. D. Johnson, M. Hossain, and J. Astone.....	75
<b>Comprehensive Primary Care for Substance Users: The Central Medical Unit Model</b>	
J. M. Shi, S. P. Henry, S. I. Molde, and P. G. O'Connor .....	76
<b>Evaluation of a Possible Pharmacologic Interaction Between Rifabutin (RIF) and Methadone (MET) in HIV+ Injecting Drug Users</b>	
L. S. Brown, Jr., R. C. Sawyer, P. K. Narang, and R. Li .....	77
<b>HIV Testing on NIDA Research Unit</b>	
R. Lee, F. Vocci, T. N. Alim, S. Kelly, and S. I. Deutsch .....	78
<b>Drug Treatment Client and Staff Attitudes Towards HIV Testing</b>	
J. Astone.....	79
<b>Acquaintance With HIV-Positive Persons and Avoidance of HIV-Infected Clients Among Drug Treatment Staff</b>	
M. A. Lodico, P. E. Evans, H. W. Clark, G. Hughes, and K. Robinson.....	80
<b>The Effect of Knowledge on Willingness to Participate in HIV Vaccine Trials</b>	
I. Fureman, K. Meyers, D. Metzger, G. Woody, A. T. McLellan, H. Navaline, T. Boney, and R. Kanter .....	81

<b>Retention of Intravenous Drug Users for Longitudinal Assessment in HIV Research and Vaccine Trials</b>	
T. Boney, M. Abrams, K. Meyers, F. Mulvaney, R. Incmikoski, D. Metzger, J. Williams, S. Dyanick, P. Green, B. Davis, A. Johnson, and G. Woody.....	82
<b>HIV Seroprevalence Among IDUs: Socio-demographic and Treatment-Related Differences Across Two In- and Out-of Treatment Cohorts</b>	
H. Navaline, D. Metzger, K. Meyers, T. Boney, A. Johnson-Wilson, J. Williams, S. Dyanick, F. Mulvaney, B. Davis, M. Abrams, P. Green, P. Oglesby, R. Davis, and G. Woody .....	83
<b>Changes in Psychological Symptomatology as a Function of Serostatus and Gender Among IDUs</b>	
R. Davis, D. S. Metzger, K. Meyers, F. D. Mulvaney, H. A. Navaline, and G. E. Woody .....	84
 <i>Opioids: Behavioral Pharmacology</i>	
<b>Nor-Binaltorphimine: A Very, Very Long Acting Kappa Opioid Antagonist in Pigeons</b>	
D. C. Jewett and J. H. Woods.....	85
<b>Effects of Naltrindole on Cocaine's Self-Administration in the Rat</b>	
K. A. Menkens, E. J. Bilsky, E. D. French, F. Porreca, C. L. Hubbell, and L. D. Reid.....	86
<b>Differential Antagonism of Response Rate-Decreasing Effects of Opioid Agonists by Beta-Funaltrexamine</b>	
J. P. West, D. Hapke, D. Morgan, R.C. Pitts, M. J. Picker, and L. A. Dykstra.....	87
<b>Tolerance and Cross-Tolerance to Effects of Various Mu Opioids on Schedule-Controlled Responding of Morphine-Maintained Squirrel Monkeys</b>	
C. E. Hughes, M. J. Picker, and L. A. Dykstra.....	88
<b>Within-Session Analysis of Effects of Haloperidol and Morphine on Behavior Maintained by Time Out From Avoidance</b>	
M. Galizio, A. Forney, M. Liborio, C. Ordronneau, and A. Thomas.....	89
<b>Chronic Nalbuphine Treatment Modifies the Rate-Decreasing Effects of Some Opioids in Pigeons</b>	
L. R. Gerak and C. P. France.....	90
<b>Discriminative Stimulus Effects of C1-977 in Pigeons</b>	
M. R. Brandt and C. P. France .....	91
<b>Characterization of the Discriminative Stimulus Effects of Kappa Opioids and Mixed-Action Opioids: Role of Training Dose and Intrinsic Efficacy</b>	
M. A. Smith and M. J. Picker.....	92

<b>Individual Differences in the Discriminative Stimulus, Rate-Decreasing and Antinociceptive Effects of High and Low Efficacy Mu Opioids</b>	
D. Morgan and M. D. Picker.....	93
<b>Animals Trained to Discriminate Morphine From Naloxone Generalize Morphine (But Not Naloxone) Control to Nalorphine</b>	
S. Smurthwaite and A. L. Riley.....	94
<b>Inhibition of CYP2D1 Enzyme Activity Alters Hydrocodone Metabolism But Not Drug Discrimination in the Rat</b>	
N. Joharchi, E. M. Sellers, T. A. Berns, S. V. Otton, and R. L. Balster .....	95
<b>Opioid Discrimination in Humans: Hydromorphone Dose-Response Curves Pre- and Post-Training at Progressively Lower Doses</b>	
K. L. Preston, R. Fromme, and G. E. Bigelow .....	96
<b>Hydrocodone (HC) Effects in Cytochrome P4502D6 (CYP2D6) Deficient Individuals</b>	
G. J. Baylon, H. L. Kaplan, U. Busto, S. W. Cheung, S. V. Otton, G. Somer, and E. M. Sellers .....	97
<i>Opioids: Physiology and Pharmacology</i>	
<b>Comparing the Subjective, Psychomotor, and Physiological Effects of Intravenous Butorphanol and Morphine in Healthy Volunteers</b>	
J. P. Zacny, J. L. Lichtor, P. Thapar, D. W. Coalson, D. Flemming, and W. Thompson .....	98
<b>Acute Opioid Physical Dependence in Humans: Pharmacological Specificity</b>	
M. K. Greenwald and M. L. Stitzer.....	99
<b>A Survey of Sleep Problems in a Substance Abuse Population</b>	
T. S. Gill, D. M. Ziedonis, C. K. Farren, E. A. Wallace, and R. S. Schottenfeld .....	100
<b>Gamma-Hydroxybutyrate: A Putative Neurotransmitter that is Abused and Causes Physical Dependence</b>	
S. L. Frederick, G. P. Galloway, F. Staggers, Jr., S. A. Stalcup and D. Smith.....	101
<b>The Effect of Gamma Hydroxybutyric Acid (GHB) on Naloxone-Precipitated Opiate Withdrawal</b>	
E. K. Hajra, M. I. Rosen, T. J. McMahon, F. A. Hameedi, and T. R. Kosten .....	102
<b>Attenuation of Opioid Withdrawal: Pharmacological Profiles of Nitric Oxide Synthase Inhibitors</b>	
D. B. Vaupel, A. S. Kimes, and E. D. London.....	103
<b>Effects of High Intravenous Doses of Dynorphin A (1-13) On Tail-Flick Latency and Central Nervous System Histology in Rats</b>	
P. R. Pentel, W. Wananukul, L. P. Hooke, C. R. N. Jones, D. K. Hatsukami, W. R. Anderson, and N. M. Lee.....	104



<b>Precipitation of Morphine Withdrawal by Buprenorphine and Butorphanol in Male and Cynomolgous Monkeys</b> H. Fukase, K. Fukuzaki, T. Koja, R. Nagata, and S. E. Lukas.....	105
<b>Intestinal Tolerance to Morphine and Precipitated Withdrawal <i>In Vivo</i></b> T. F. Burks, G. C. Rosenfeld, and C. L. Williams .....	106
<b>Two Different Antagonisms of Nor-BNI Against Morphine on Intestinal Transit in Mice</b> T. Endoh, Y. Takezawa, and H. Nagase.....	107
<b>Respiration Frequency is Increased in Rhesus Monkeys During Morphine Withdrawal</b> C. A. Paronis and J. H. Woods .....	108
<b>Modification of Respiratory Effects of Levorphanol by Nalbuphine, Butorphanol, and Buprenorphine in Rhesus Monkeys</b> A. Liguori, W. H. Morse, and J. Bergman .....	109
<b>Swim Stress Immobility and Pituitary Adrenal Cortical Activity in Opioid Withdrawal</b> K. Grasing and S. Bailey.....	110
<b>Are There Two Delta Opioid Receptors Having Opposing Effects on Plasma Corticosterone?</b> R. M. Eisenberg.....	111
<b>Lack of Involvement of Opiate Receptors in the Dextrorphan-Induced Increase in Plasma ACTH in the Rat</b> R. N. Pechnick, R. E. Poland, and G. L. Brammer .....	112
<b>Influence of Adrenal Steroid Status Upon the Behavioral Effects of Morphine</b> T. Stoehr, O. F. X. Almeida, and T. S. Shippenberg.....	113
<b>Corticotrophin-Releasing Hormone (CRH) mRNA Diurnal Rhythms in Rat Hypothalamus and Frontal Cortex and Inhibition by Dexamethasone</b> Y. Zhou, R. Spangler, A. Ho, K. S. LaForge, V. Yuferov, E. M. Unterwald, and M. J. Kreek .....	114
<b>Effects of Drug-Induced Immunosuppression on Morphine Analgesia in Rats</b> J. U. Adams and M. W. Adler.....	115
<b>Evaluation of the Novel Kappa Opioid Agonist CI-977 (Enadoline) in Neonatal and Adult Rats</b> C. R. McLaughlin and M. E. Abood.....	116
<b>Interactions Between Cholecystinin (CCK) and Selective <math>\mu</math> and <math>\kappa</math> Opioid Receptor Agonists in the Periaqueductal Gray (PAG) of the Rat</b> L. Xin, E. B. Geller, G. H. Sterling, M. R. McCafferty, and M. W. Adler.....	117

<b>The Role of Brain <math>\mu</math>, <math>\delta</math> and <math>\kappa</math> Opioid Receptors in Analgesia Induced by Electroacupuncture Stimulation of Different Frequencies: The Rat Cold Water Tail-Flick Test</b>	
X. H. Chen, E. B. Geller, and M. W. Adler.....	118
<b>Morphine and Ketorolac Reverse Bradykinin-Induced Allodynia in the Warm-Water Tail Withdrawal Assay in Rhesus Monkeys</b>	
M. B. Gatch, S. S. Negus, E. R. Butelman, and J. H. Woods.....	119
<b>Antinociceptive Profile of SNC 80, A Highly Selective, Non-Peptic Delta Opioid Agonist</b>	
E. J. Bilsky, R. N. Bernstein, P. Davis, S. Calderon. K. C. Rice, R. B. Rothman, and F. Porreca.....	120
 <i>Opioids: Chemistry and Molecular Biology</i>	
<b>Kappa Opioid Receptors on Three Related Thymoma Cell Lines are Coupled to Adenylyl Cyclase With Different Efficiency</b>	
D. M. P. Lawrence, D. B. Joseph, and J. M. Bidlack.....	121
<b>Down-Regulation of Mu Opioid Binding Sites Following Continuous ICV Infusion of NPFF and Morphine: An Autoradiographic Study</b>	
J. L. Cadet, C. B. Goodman, B. Emilien, and R. B. Rothman.....	122
<b>Resolution of Subtypes of the <math>k_{2a}</math> and <math>k_{2b}</math> Opioid Receptor in Guinea Pig Brain Using [<math>^{125}</math>I]IOXY</b>	
Q. Ni, H. Xu. J. S. Partilla, B. R. de Costa, K. C. Rice and R. B. Rothman.....	123
<b>The Non-peptide Delta Agonist, BW373U386, its Enantiomers, and Related Compounds: Interactions at Multiple <math>\delta_{ncx}</math> Binding Sites in Mouse Brain</b>	
H. Xu, J. S. Partilla, S. N. Calderon, K. C. Rice, F. Porreca, and R. B. Rothman.....	124
<b>The Non-peptide Delta Agonist, BW 373U86, its Enantiomers, and Related Compounds: Interactions at Multiple <math>\delta_{cx}</math> Binding Sites in Rat Brain</b>	
X. Y. Cha, H. Xu, S. N. Calderon. K. C. Rice, F. Porreca, and R. B. Rothman.....	125
<b>New Synthetic Approaches to Oxide-Bridged 5-Phenylmorphans as Probes for Opioid Receptors</b>	
E. Ohshima, S. Kodato. K. Yamada, R. B. Rothman, H. Xu, A. E. Jacobson, and K. C. Rice.....	126
<b>Synthesis and Biological Evaluations of <math>6\beta</math>- and <math>6\alpha</math>-IODO-3,14-Dihydroxy-17-Methyl-4,5 <math>\alpha</math>-Eoxymorphinans</b>	
H. Kayakiri, J. L. Flippen-Anderson, C. George, R. B. Rothman, H. Xu, J. S. Partilla, and K. C. Rice.....	127

<b>Ring Constrained Analogs of Buprenorphine</b>	
A. Coop, J. W. Lewis, J. R. Traynor, and L. Gu .....	128
<b>Disposition of Codeine in Human Hair Following Single and Multiple Doses</b>	
D. E. Rollins, D. G. Wilkins, G. G. Krueger, and R. L. Foltz.....	129
<b>A Gas Chromatographic/Positive Ion Chemical Ionization Mass Spectrometric Method for Determination of 1<math>\alpha</math>-Acetylmethadol and its Two N-Demethylated Metabolites in Plasma and Urine</b>	
D. E. Moody, D. J. Crouch, C. O. Sakashita, M. E. Alburges, K. Minear, J. E. Schulthies, and R. L. Foltz.....	130
<b>The Pharmacokinetics of LAAM, NORLAAM and DINORLAAM Following Oral Dosage of LAAM</b>	
C. N. Chiang, C. Marschke, R. Hawks, D. Collins, and A. Forrest .....	131
<b>Plasma Concentrations of LAAM, NLAAM and DNLAAM in Fetal and Material Rats Orally Administered Escalating Doses of LAAM for 11 Weeks Prior to Mating</b>	
M. E. Alburges, D. E. Moody, R. G. York, N. Chiang, H. Sorer, and J. A. Nuite-Belleville .....	132
 <i>Pharmacological Treatment: Methadone</i>	
<b>Developmental Outcomes in Rabbits Associated with Chronic LAAM Exposure</b>	
R. G. York, H. Sorer and J. A. Nuite-Belleville.....	133
<b>Acute 7-Day and 30-Day Toxicity of LAAM and NLAAM in Male and Female Sprague-Dawley Rats</b>	
J. F. Borzelleca, J. L. Egle, Jr., L. S. Harris, D. N. Johnson, J. B. Terrill, and J. A. Nuite-Belleville .....	134
<b>Correlation of LAAM Plasma Levels with Subject-Reported Positive and Negative Effects, Adverse Experiences, and Concomitant Medication Use</b>	
E. Yu, K. Kampman, and P. J. Fudala.....	135
<b>Treatment Success and Failure in Opiate-Dependent Treatment-Research Patients: Psychopathological and Other Correlates</b>	
P. J. Fudala, I. D. Montoya, J. M. Hess, J. W. Cornish, J. H. Jaffe, and R. E. Johnson.....	136
<b>Psychological Characteristics of IVDUs in an Enhanced Methadone Maintenance Program</b>	
S. E. Wugalter, C. E. Grella, and M. D. Anglin.....	137
<b>Mood Effects of Methadone or Placebo in Methadone Maintenance Patients</b>	
J. M. Peirce, S. J. Nixon, G. K. Borrell and F. A. Holloway.....	138

<b>Depression in Injecting Drug Users Enrolled in Methadone Maintenance Treatment</b>	
M. M. Lin, L. S. Brown, Jr., T. J. Meyer, and N. Siddiqui.....	139
<b>Expectations of Abstinence During Methadone Maintenance: Psychological Correlates and Relation to Heroin Use</b>	
D. A. Wasserman, S. M. Hall, and B. E. Havassy .....	140
<b>Is There Evidence of Interviewer-Patient Matches in Judgements Made About the Severity of Substance Abuse Problems?</b>	
A. R. Zaballero and L. S. Brown, Jr. ....	141
<b>Characteristics of Patients Entering Community Based Methadone Maintenance and Implications for Matching Patients to Interventions</b>	
A. F. Chu, L. S. Brown, Jr., B. Wallace, M. M. Lin, and A. Zaballero.....	142
<b>Predictors of Methadone Treatment Outcome</b>	
A. J. Saxon, C. Fleming, T. R. Jackson, E. A. Wells, and D. A. Calsyn.....	143
<b>Reducing Subject Attrition in Drug Abuse Studies: Identifying Attrition Risk Factors and Techniques to Improve Follow-up</b>	
D. DePhilippis and D. S. Metzger.....	144
<b>Problem Gambling Among Former Opiate Addicts: Investigating the Correlates of Dual Addiction</b>	
W. Feigelman, P. H. Kleinman, H. R. Lesieur, R. B. Millman, and M. L. Lesser.....	145
<b>Why Do Methadone Clients Volunteer for Research? Reasons for Volunteering as Correlates of Success in a Research Project and in Methadone Treatment</b>	
S. D. Husband and J. J. Platt.....	146
<b>Teaching Parenting Skills to Drug Addicted Parents in Methadone Treatment</b>	
R. R. Gainey, K. P. Haggerty, R. F. Catalano, and M. J. Hoppe.....	147
<b>Maintaining the Status Quo: Stages of Change Among Polydrug Users in Methadone Treatment</b>	
M. A. Belding, M. Y. Iguchi, and R. J. Lamb .....	148
<b>Are All Persons With ASP “True” Psychopaths?</b>	
B. L. Kail, P. H. Kleinman, R. B. Millman, M. L. Lesser, and H. Robinson .....	149
<b>Two Year Predictive Validity of Psychopathy Versus Antisocial Personality Disorder Diagnoses</b>	
A. I. Alterman, M. J. Rutherford, J. S. Cacciola, and J. R. McKay.....	150
<b>Psychopathy, Antisocial Personality, and Other Personality Disorders in Opioid Addicts: Assessment and Treatment Issues</b>	
N. A. Piotrowski, D. J. Tusel, K. L. Sees, P. Banys, and S. M. Hall.....	151

<b>History of Post-Traumatic Stress Disorder and Current Treatment Goals for Opioid Addicts in Methadone Treatment</b>	
P. S. Meek, N. A. Piotrowski, D. J. Tusel, and S. M. Hall.....	152
<b>Behavioral Contingent Pharmacotherapy in the Treatment of Opioid Dependent Patients</b>	
M. Kidorf, R. K. Brooner, and V. L. King.....	153
<b>Contingent Contract Failures Improve Upon Re-admission When the Same Contingencies are Applied</b>	
D. A. Calysn, E. A. Wells, A. J. Saxon, R. Jackson, and V. Stanton.....	154
<b>Contingency Contracting for Illicit Drug Use With Opioid Addicts in Methadone Treatment</b>	
D. J. Tusel, N. A. Piotrowski, K. Sees, P. M. Reilly, P. Banys, P. Meek, and S. M. Hall.....	155
<b>Resource→Procedure→Process→Outcome Analysis (RPPOA): Preliminary Findings of Cost-Effectiveness Analysis of a Methadone Maintenance Program</b>	
B. T. Yates, K. J. Besteman, J. Filipczak, L. Greenfield, and A. De Smet .....	156
<b>The SF-36 As A Measure of Substance Abusers' Health Perceptions</b>	
L. Greenfield, K. Besteman, C. Clark, J. Filipczak, and B. Yates .....	157
 <i>Pharmacological Treatment: Buprenorphine</i>	
<b>What Dose of Buprenorphine Reduces Opiate Use? A Double-Blind Dose-Ranging Study</b>	
P. Compton, W. Ling, C. Charuvastra, D. Wesson, and C. J. Klett .....	158
<b>Negative Opiates in Urine of Patients on Buprenorphine Study</b>	
R. I. H. Wang and L. D. Young.....	159
<b>A Pilot Study of Primary Care-Based Buprenorphine Maintenance</b>	
P. G. O'Connor, A. Oliveto, J. M. Shi, K. M. Carroll, B. J. Rounsaville, and T. R. Kosten.....	160
<b>Triple Buprenorphine Maintenance Doses Maintain Opioid-Dependent Outpatients for 72 Hours With Minimal Withdrawal</b>	
W. K. Bickel, L. Amass, J. P. Crean, and S. T. Higgins.....	161
<b>Daily Versus Alternate-Day Dosing of Buprenorphine in the Outpatient Treatment of Opioid Dependence</b>	
R. E. Johnson, M. L. Stitzer, E. C. Strain, G. E. Bigelow, and I. A. Liebson.....	162
<b>Alternate-Day Buprenorphine Dosing is as Effective as, and is Preferred to, Daily Dosing in Opioid-Dependent Humans</b>	
L. Amass, W. K. Bickel, J. P. Crean, and S. T. Higgins .....	163

<b>A Survey of Potential Program and Community-Based Reinforcers for Use in Opioid Treatment</b>	
J. P. Crean, L. Amass, W. K. Bickel, and S. T. Higgins .....	164
<b>Buprenorphine-Naloxone Combination Drug for the Treatment of Drug Addiction</b>	
R. Hawks and C. N. Chiang.....	165
<b>Improving the Hedonic and Gustatory Qualities of Sublingual Naloxone with Various Flavoring Agents</b>	
J. Mendelson and R. T. Jones.....	166
<b>Inpatient Medically Supervised Opioid Withdrawal with Buprenorphine Alone or in Combination with Naltrexone</b>	
D. J. Mann, I. D. Montoya, C. Contoreggi, P. A. Ellison, W. R. Lange, and K. L. Preston.....	167
<b>Withdrawal From Chronic Buprenorphine Administration: Preliminary Findings</b>	
A. M. Washburn, L. Brooks, S. L. Batki, D. Tusel, N. Nanda, and K. White.....	168
 <i>Perinatal Exposure to Drugs of Abuse</i>	
<b>Ritanserin (RIT) Blocks the Vasoconstriction Caused by Injection of Cocaine (COC) Into Chicken Eggs with 15 Day-Old Embryos</b>	
S. B. Sparber, A. Wasserman, and G. Bollweg .....	169
<b>Ritanserin (RIT) Injected Into Eggs with Chicken Embryos on E-14 Does Not Affect Detour Learning 1-2 Weeks After Hatching</b>	
C. Bollweg and S. B. Sparber.....	170
<b>Mild Stress Raises Serum Corticosterone (CORT) Levels in Two Week-Old Chicks Hatched from Eggs Injected on E-14 with A High Dose of Ritanserin (RIT) More Than in Controls</b>	
Y. X. Wei and S. B. Sparber .....	171
<b>Evidence of • OH Free Radicals in Hearts and Brains of Chick Embryos After Cocaine (COC) Injection</b>	
M. A. Kubak and S. B. Sparber .....	172
<b>Short Term Subcutaneous Cocaine Administration During Pregnancy Does Not Alter Stress Hormone Levels in Postpartum Dams</b>	
G. Battaglia, T. Cabrera, L. D. Van de Kar, Q. Li, and W. Pinto .....	173
<b>Maternal Cocaine During Pregnancy, Via Intravenous Access Port, Alters Fetal Neurobehavioral Development</b>	
C. F. Mactutus and R. M. Booze .....	174
<b>CNS Development and Mother-Father Interactions Among Cocaine Exposed Infants: A Preliminary Report</b>	
P. E. Suess, M. A. Owrutsky, and R. I. Herning.....	175
<b>Primary Care Interventions for Cocaine Abusing Pregnant Women</b>	
R. S. Schottenfeld, B. Forsyth, S. Ball, J. Pakes, and C. Brady.....	176

<b>Cessation of Cocaine Use During Pregnancy: A Preliminary Comparison</b>	
R. Elk, J. M. Schmitz, L. Manfredi, H. Rhoades, R. Andres, and J. Grabowski .....	177
<b>Types of Abuse and Cocaine Use in Pregnant Women</b>	
K. Jantzen, S. Ball, and R. Schottenfeld.....	178
<b>Enhanced Program Retention of Perinatal Substance Abusers Following Patient Incentive Program</b>	
J. H. Lee and D. Svikis .....	179
<b>Pediatric Outcomes in Infants of Pregnant Drug Abusing Women</b>	
L. Jansson, D. Svikis, P. Paluzzi, and F. Hackerman .....	180
<b>Impact of an Enhanced Model of Prenatal Care for Substance Abusers in a Comprehensive Treatment Program</b>	
P. A. Paluzzi, J. Emerling, J. Leiva, P. Gazaway, and G. Huggins .....	181
 <i>Risk Factors for Substance Abuse</i>	
<b>An Examination of Perceived Risks and Behavior Among Adolescents in Therapeutic Communities</b>	
G. Bhattacharya, N. Jainchill, J. Yagelka, K. J. Hindmand, and S. Holland .....	182
<b>Personality Profiles of Drug Dependent Subjects</b>	
K. Boyle and M. Maglione .....	183
<b>Substance Use and People Seeking Disability Services</b>	
D. Moore and S. C. Acquilano .....	184
<b>Nurses' Drug Use: New NIDA Funded Research</b>	
A. Trinkoff and C. Storr .....	185
<b>Addiction Among Anesthesiology Personnel - A Five-Case Report</b>	
Y.-F. Sung .....	186
<b>Drug Use and Other Risk Behaviors Among Hospital Emergency Room Patients</b>	
J. Chen, Y. H. Hser, K. Boyle, M. Orlinsky, H. Fagelson, and R. Hutson.....	187
<b>Drug Use and Other Risk Factors Among STD Patients</b>	
D. Longshore, Y. H. Hser, K. Boyle, D. Anglin, and G. Richwald .....	188
<b>Perceived Need for Drug Treatment Among Pregnant Arrestee Women and Arrestee Mothers in Los Angeles</b>	
D. M. Baldwin and M. D. Anglin.....	189

**Oral Communications**

*Nicotine: Basic and Clinical Research*

**Comparative SAR Studies of N-Substituted Nornicotines and N-Substituted Norbridged Nicotines**  
W. Glassco, E. L. May, M. I. Damaj, and B. R. Martin..... 190

**Lobeline Robustly Increases [<sup>3</sup>H] Dopamine Release from Rat Striatal Slices**  
L. P. Dwoskin, L. H. Teng, S. T. Buxton, and P. A. Crooks..... 191

**Time Course of Dissipation of Acute Tolerance to Nicotine in Smokers**  
K. A. Perkins, J. E. Grobe, and S. Mitchell..... 192

**The Role of Nicotine Delivery Rate in Development of Selectively Targeted Medications**  
J. E. Henningfield, A. J. Jenkins, K. Steinberg, R. M. Keenan, and E. J. Cone..... 193

**A Nicotine Patch Reduces Subjective and Objective Measures of Tobacco Withdrawal**  
W. B. Pickworth, M. F. Butschky, and J. E. Henningfield ..... 194

**Pilot Study of a Nicotine Vaporizer for Smoking Cessation**  
S. J. Keischow, F. Nilsson, M. Franzon, A. Hill, and P. Otte..... 195

**Psychological Treatment, Nicotine Gum, and Depression in Study Treatment**  
S. M. Hall, R. Munoz, V. Reus, K. Sees, G. Humfleet, and C. Duncan ..... 196

**Tobacco Smoking, Tobacco Dependence and Sustained Bouts of Depressed Mood**  
E. O. Johnson and J. C. Anthony..... 197

**Efficacy of Free Transdermal Nicotine in Indigent Smokers**  
T. S. Howard, J. R. Hughes, and D. Dameron ..... 198

*Special Issues Related to Opioid Addiction*

**Risk Factors for Starting Illicit Drug Use Among Youths With No Conduct Disorder**  
C. G. Schutz and J. C. Anthony..... 199

**Association Between Illicit Drug Use and Behavioral Repertoires in Middle School Students**  
C. E. Johanson and J. C. Anthony ..... 200

**Service Needs of Injection Drug Users: Gender Differences**  
D. A. Mathis, H. Navaline, D. S. Metzger, and J. J. Platt..... 201



<b>Evaluating the Treatment Needs of Opiate-Addicted Women</b> K. G. Walsh, S. S. Luthar, T. J. McMahon, and R. S. Schottenfeld.....	202
<b>Reduction in Addiction Severity Among African-American and Hispanic Patients Receiving Standard Methadone Maintenance: Six-Month Treatment Outcome</b> B. C. Wallace, L. S. Brown, Jr., A. F. Chu, M. M. Lin, and A. Zaballero.....	203
<b>Vietnam Drug Users Two Decades Later. I. Mortality Results</b> R. K. Price, S. A. Eisen, K. S. Virgo, K. S. Murray, and L. N. Robins.....	204
<b>Attitudes, Knowledge, and Behavior Concerning TB Among Drug Treatment Providers in Two California Cities</b> H. W. Clark, D. DePhilippis, P. Evans, G. Hughes, M. Lodico, K. Robinson, and J. Sorensen .....	205
<b>Oral Communications</b>	
<i>Polydrug Abuse</i>	
<b>The Effects of Morphine on the Selection of Sucrose and Ethanol</b> M. F. Stromberg, J. R. Volpicelli, B. L. Slifer, S. C. Meister, and R. R. Ulm.....	206
<b>Ethanol Attenuates the Severity of Naloxone-Precipitated Opiate Withdrawal</b> T. A. Kosten, S. Muly, and W. J. Shoemaker .....	207
<b>A Primate Model of Polydrug Abuse: Implications for Evaluation of New Medications</b> N. K. Mello, S. S. Negus, S. E. Lukas, J. M. Drieze, and J. H. Mendelson .....	208
<b>No Evidence for Ventriculomegaly in Polysubstance Abusers: A Volumetric Magnetic Resonance Imaging Study</b> X. Liu, R. L. Phillips, S. M. Resnick, D. F. Wong, J. M. Stapleton, V. L. Villemagne, and E. D. London .....	209
<b>Buprenorphine Treatment Improves Brain Perfusion Abnormalities in Men with Concurrent Cocaine and Heroin Dependence: A SPECT Brain Imaging Analysis</b> J. H. Mendelson, B. L. Holman, S. K. Teoh, J. Levin, and N. K. Mello.....	210
<b>Depression in Cocaine Abusing Opioid Addicts Treated with Either Buprenorphine or Methadone</b> D. M. Ziedonis, C. Farren, and T. R. Kosten.....	211
<b>Differential Reinforcement of Sustained Cocaine Abstinence in Intravenous Polydrug Abusers</b> K. Silverman, S. T. Higgins, R. K. Brooner, I. D. Montoya, C. R. Schuster, and K. L. Preston.....	212

<b>Marijuana Use in Cocaine-Dependent Patients: Assessment and Treatment</b>	
A. J. Budney, S. T. Higgins, W. K. Bickel, and M. L. Van Etten.....	213
<b>The Prevalence of Nicotine and Caffeine Use and Dependence Among Alcoholics and Non-Alcoholics</b>	
K. L. Hale and J. R. Hughes.....	214
<b>Drug Treatment Histories of Individuals Abusing a Single Drug Compared to Histories of Polydrug Abusers</b>	
S. B. Greberman, J. DeWeese, and D. Jasinski.....	215
 <i>Clinical Research on Stimulant Effects</i>	
<b>Discriminative Stimulus Effects of Ephedrine and Phenylpropanolamine</b>	
L. M. Schuh, S. J. Heishman, B. Lewis, and J. E. Henningfield.....	216
<b>Subjective Effects of Intravenous Caffeine in Drug Abusers</b>	
R. R. Griffiths, C. R. Rush, and J. T. Sullivan.....	217
<b>Methylphenidate Effects in Cocaine Dependent Patients: Laboratory Assessment and Treatment Outcome</b>	
J. D. Roache, W. Thompson, J. Schmitz, and J. Grabowski.....	218
<b>Effect of AMPT on Response to Cocaine Challenge</b>	
S. M. Stine, I. L. Petrakis, P. I. Jatlow, J. H. Krystal, T. R. Kosten, and D. S. Charney.....	219
<b>Limbic Activation by IV Procaine in Cocaine Addicts</b>	
B. Adinoff, K. Brady, S. Sonee, S. Katz, and C. H. Kellner.....	220
<b>Effects of Acute and Repeated Intravenous Cocaine in Humans Maintained on Methadone</b>	
R. W. Foltin, M. W. Fischman, F. R. Levin, A. Couraud, and I. Christiansen.....	221
<b>Cocaethylene: Pharmacology, Physiology, and Behavioral Effects in Humans</b>	
E. F. McCance-Katz, T. R. Kosten, L. H. Price, and P. Jatlow.....	222
<b>Comparison of Plasma Concentrations and Pharmacokinetics of Cocaine and Cocaethylene in Human Subjects Given the Drugs Intravenously</b>	
C. E. Cook, A. R. Jeffcoat, M. A. Myers, B. F. Thomas, Y. -W. Lee, F. R. Ley, K. Sihler, and M. Perez-Reyes.....	223
<b>A Laboratory Model of the Self-Administration of Smoked Cocaine</b>	
B. Lexau and D. Hatsukami.....	224

*Alcohol: Basic and Clinical Research*

<b>Alcohol Preferring (HAD) Rats Have Reduced Dopamine Transporter but Not Serotonin Transporter Densities</b>	
J. W. Boja and M. D. Schechter .....	225
<b>Antagonism of Serotonin Type 2 Receptors by Spiperone Reverses Anxiety-Like Behaviors During Ethanol Withdrawal in Rats</b>	
H. Lal, S. M. Rezazadeh, and C. J. Wallis .....	226
<b>The Effects of Chronic Alcohol Self-Administration on the Menstrual Cycle in Female Rhesus Monkeys</b>	
J. M. Drieze, N. K. Mello, J. H. Mendelson, and N. Diaz-Migoyo .....	227
<b><i>In Vivo</i> Proton Magnetic Resonance Spectroscopy Detection of Acute Alcohol Tolerance in Humans</b>	
M. J. Kaufman, T. -M. Chiu, J. H. Mendelson, B. T. Woods, S. K. Teoh, M. Eros-Samylai, G. Mercer, and N. K. Mello.....	228
<b>Effects of Ethanol on Regional Cerebral Metabolic Rate in Normal Volunteers: Technological Advances</b>	
H. de Wit, J. Metz, D. Dooley, J. Roemer, and M. Cooper.....	229
<b>Effects of Naltrexone on Alcohol Drinking: Preliminary Findings</b>	
A. C. King, J. R. Volpicelli, R. N. Ehrman, A. Alterman, N. T. Watson, A. Frazer, and C. P. O'Brien.....	230
<b>Effects of Naltrexone Pretreatment on Acute Responses to Ethanol in Social Drinkers</b>	
P. Doty and H. de Wit .....	231
<b>Combined Serotin and Dopamine Indirect Agonists Correct Alcohol Associated Neuroses</b>	
P. Hitzig.....	232
<b>Preliminary Outcome of Cue Exposure Treatment for Alcohol Dependence</b>	
J. D. Greeley, J. Pead, T. Murray, S. Pahoki, A. Ritter, B. Felstead, R. P. Mattick, and N. Heather .....	233
<b>Role of Expectancy in Persistent, Remitted and Emergent Alcohol Dependence</b>	
M. M. Kilbey, K. Downey, and N. Breslau.....	234
 <b><i>Benzodiazepines: Basic and Clinical Research</i></b>	
<b>Effects of Full and Partial Allosteric Modulators of GABA<sub>A</sub> Receptors on Complex Behavioral Processes</b>	
J. Auta and J. Moerschbaecher .....	235
<b>Suppression of Maximal Benzodiazepine Withdrawal by Pro-GABA-Ergic Drugs I. Chlordiazepoxide, Phenobarbital, Sodium Bromide and Baclofen</b>	
N. R. Boisse, O. Amitay, and J. Leung.....	236

<b>Sex Differences in Spontaneous Withdrawal Following Acute Benzodiazepine Dependence Induction</b>	
J. Leung, N. R. Boisse, and O. Amitay .....	237
<b>Contingent Anticonvulsant Tolerance Develops to the Benzodiazepine (BZ) Partial Agonist, Bretazenil (R016-60280, but Not to Clonazepam</b>	
E. I. Tietz, W. Ferencak, L. Aloe, and H. Chang.....	238
<b>RO 15-1788 has Agonist Properties in the Pigeon but Not in the Rat or Squirrel Monkey in Models of Working Memory</b>	
A. Nordholm, D. Wright, and G. R. Wenger .....	239
<b>Acute Behavioral and Self-Reported Effects of Zolpidem, Triazolam and Temazepam in Normal Volunteers</b>	
C. R. Rush, J. M. Frey, and R. R. Griffiths .....	240
<b>Cumulative Dosing for Human Triazolam Discrimination Using a Novel Response Procedure</b>	
B. J. Smith, W. K. Bickel, S. T. Higgins, J. R. Hughes, and J. B. Kamien.....	241
<b>Abuse Liability of Triazolam, Meprobamate and Butobarbital: A Public Health Issue</b>	
L. Zawertailo, U. Busto, K. L. Kaplan, and E. M. Sellers.....	242
<b>Abuse Liability Assessment of Suriclone: A Cyclopyrrolone Anxiolytic</b>	
J. T. Sullivan, M. P. Testa, and D. R. Jasinski .....	243
 <i>Cocaine: Neurobiology and Behavioral Pharmacology</i>	
<b>Cocaine Interactions with Serotonin 5-HT<sub>3</sub> and Dopamine Receptors: Studies of the 5-HT<sub>3</sub> Agonist 1-(META-Chlorophenyl)-Biguanide (mCPB) as a Discriminative Stimulus in the Rat</b>	
R. De la Garza, II, P. M. Callahan, and K. A. Cunningham .....	244
<b>Characterization of Serotonergic Involvement in the Behavioral-Stimulant and Reinforcing Effects of Cocaine in the Squirrel Monkey</b>	
L. L. Howell and L. D. Byrd.....	245
<b>Extracellular Serotonin During Abstinence from Extended Cocaine Self-Administration: Decreased Levels and Evidence for an Enhanced 5HT/DA Interaction</b>	
L. H. Parsons, G. F. Koob, and F. Weiss.....	246
<b>Characterization of the Discriminative Stimulus Effects of Benztropine, A Potential Cocaine Therapeutic Agent</b>	
J. B. Acri, A. H. Newman, M. Chider, and J. M. Witkin.....	247
<b>Role of Conditioning in the Phasic Firing Patterns of Nucleus Accumbens Neurons Exhibited During Cocaine Self-Administration in Rats</b>	
R. M. Carelli and S. A. Deadwyler .....	248

<b>The Progressive-Ratio (PR) Schedule as a Measure of the Relative Reinforcing Properties of the Combination of Cocaine and Heroin (“Speedball”) with Each Component Alone</b> J. Francher, C. Duvauchelle, T. Sapoznik, and C. Kometsky.....	249
<b>Administration in Rats: The Effect of SCH23390</b> Y. Egilmez, M. W. Emmett-Oglesby, and J. D. Lane.....	250
<b>Self-Administration of the Dopamine Uptake Inhibitor Nomifensine Into Nucleus Accumbens of Rats</b> R. A. Wise and W. A. Carlezon, Jr. ....	251
<i>Opioids: Pharmacotherapy and Pharmacology</i>	
<b>Study of Dynorphin A Peptides <i>In Vitro</i> Processing in Human Blood by Matrix-Assisted Laser Desorption Mass Spectrometry</b> J. Z. Chou, B. T. Chait, R. Wang, and M. J. Kreek.....	252
<b>Tolerability Study of a Depot Form of Naltrexone Substance Abusers</b> T. N. Alim, B. Tai, C. N. Chiang, T. Green, R. B. Rosse, T. Lindquist, and S. I. Deutsch.....	253
<b>A Comparison of Buprenorphine’s and Naltrexone’s Opioid Blockade Abilities</b> K. J. Schuh, S. L. Walsh, and M. L. Stitzer .....	254
<b>The Pharmacokinetics Studies of LAAM: Clinical Correlates</b> M. Beckson, W. Ling, F. Vocci, W. Pickworth, P. Fudala, J. Wilkins, and K. Clagett-Carr .....	255
<b>Buprenorphine and Naloxone Interactions in Heroin Dependent Volunteers</b> R. T. Jones and J. Mendelson.....	256
<b>The Effect of Clonidine on Naloxone-Precipitated Opiate Withdrawal</b> M. I. Rosen, T. J. McMahon, F. A. Hameedi, and T. R. Kosten.....	257
<b>Abuse Liability Evaluation of Buprenorphine in Buprenorphine-Treated Patients</b> E. C. Strain, S. L. Walsh, K. L. Preston, I. A. Liebson, and G. E. Bigelow.....	258
<b>LAAM Labeling Assessment Study:, Retention, Dosing, and Side Effects in a 64 Week Study</b> S. Herbert, A. Montgomery, P. Fudala, F. Vocci, J. Gampel, J. Mojsiak, J. Hill, and R. Walsh.....	259
<b>Routes of Prior Opiate Administration: Effects on Outcome Variables in the NIDA/MDD #999a Buprenorphine Multicenter Study</b> D. L. Segal and J. L. Hill.....	260

**Poster Session**

*Nicotine*

**Correlates of Maternal Smoking Among Blacks and Whites**  
P. Andreski and N. Breslau.....261

**Caloric Restriction Increases Smoking in Nicotine-Dependent Adults**  
L. J. Cheskin, J. Hess, L. Wiersema, J. E. Henningfield, and  
D. A. Gorelick .....262

**Assessing Severity of Nicotine Dependence**  
K. L. Sees, D. T. Hartz, R. F. Munoz, and S. M. Hall.....263

**Effect of Cue-Type and Cigarette Availability on Craving and Smoking Behavior**  
A. Droungas, R. Ehrman, A. R. Childress, and C. P. O'Brien.....264

**Cue Reactivity in Smoking Cessation: Can Reactivity Predict Outcome?**  
V. W. Rees, J. D. Greeley, and R. F. Westbrook..... 265

**Stages of Change and Cigarette Smoking Among Chronic Psychiatric Patients Living in Supervised Living Settings**  
R. G. Hall, M. DuHamel, R. McClanahan, G. Miles, C. Nason,  
P. Schiller, L. Tao-Yonenaga, and S. M. Hall.....266

**Impact of Inpatient Substance Abuse Treatment on Cigarette Smoking**  
R. I. Kim, K. L. Sees, and K. L. Delucchi.....267

**Combining Individual Relapse Prevention Counseling with a Transdermal Nicotine Patch for Smoking Cessation**  
P. Lifrak, P. Gariti, A. Alterman, J. Volpicelli, L. Epperson,  
L. D'Angelo, A. Sharf, E. Green, and C. O'Brien .....268

**Validity of the Sachs Optimum Dosing Algorithm (SODA) for Determining Nicotine Patch Dose to Optimize Tobacco Dependence Treatment**  
D. P. L. Sachs, N. L. Benowitz, A. G. Bostrom, and  
M. D. Hansen..... 269

**Effects of Nicotine on Cooperative Responding in Abstinent Male and Female Smokers**  
M. Broitman, R. Spiga, J. Schmitz, R. Elk, and  
R. H. Bennett..... 270

**Selegiline Fails to Alter Cigarette Consumption in Cocaine-Dependent Subjects**  
T. M. Gendron, J. Mahaffey, L. E. Thomson, L. Kahler,  
J. E. Henningfield, D. A. Gorelick, J. L. Cadet, and  
R. B. Rothman.....271

**Effects of Target Criteria and Reinforcement Magnitude in Reinforcing Reduced Breath CO Levels in Smokers Not Seeking Treatment**  
R. J. Lamb, M. Y. Iguchi, and K. C. Kirby.....272

## *Caffeine*

- Effects of D1- and D2-Dopamine Receptor Agonists Alone and Combined on Locomotor Activity of Caffeine-Tolerant Rats**  
B. E. Garrett and S. G. Holtzman ..... 273
- Quantitative EEG Changes During Caffeine Withdrawal**  
R. R. Reeves, F. A. Struve, G. Patrick and J. A. Bullen ..... 274
- Does Caffeine Cessation Increase Firing Rates of Paroxysmal EEG Dysrhythmias: A Serendipitous Observation**  
G. Patrick, R. Reeves, and F. Struve ..... 275
- Effects of Caffeine on Cooperative Responding**  
S. Rafieha, R. Spiga, and M. Broitman ..... 276
- Interactions of Alprazolam and Caffeine: Effects on DRL Performance**  
C.E. Lau and J. L. Falk ..... 277
- Alcohol, Sedative-Hypnotics and Anxiolytics*
- Serotonin (5HT) Involvement in the Discriminative Stimulus Effects of Benzodiazepines (BZ)**  
H. C. Chen and M. E. Bronson ..... 278
- Contextual Stimuli and Reversal Learning: Interaction in a Drug Discrimination Task**  
T. U. C. Jarbe and D. A. Mathis ..... 279
- Tolerance and Cross-Tolerance Between Ethanol and Diazepam in Rats Trained to Detect Ethanol**  
D. A. Lytle and M. W. Emmett-Oglesby ..... 280
- Preferences for Ethanol and Diazepam in Anxious Individuals: An Evaluation of the Self-Medication Hypothesis**  
M. A. D. Chutuape and H. de Wit ..... 281
- Effects of Pentylentetrazole (PTZ) on Anxiety and Ethanol Self-Administration in Male Wistar Rats**  
Y. Buczek, D. M. Tomkins, and E. M. Sellers ..... 282
- Effects of Oral Triazolam Pre-treatment on Drinking in Baboons: Differential Effects Depending Upon Self-Administration History**  
M. A. Kautz and N. A. Ator ..... 283
- The Acute Effects of Beta-Carboline-3-Carboxylate-Ethyl Ester (B-CCE) on Acquisition in Squirrel Monkeys**  
U. C. Savage and J. M. Moerschbaeher ..... 284
- Pentobarbital and Diazepam Have Similar Effects on Visual and Spatial Memory in Pigeons**  
G. R. Wenger, E. Moore, and A. Nordholm ..... 285
- Physical Dependence on Nordiazepam in Rats**  
X. Jing, E. P. Wala, and J. W. Sloan ..... 286

<b>Ethanol Inhibits Forskolin-Stimulated cAMP Formation in Human Neuroblastoma Cells</b>	
S. M. Rezazazdeh, H. Lal, and M. W. Martin.....	287
<b>A Rat Model of “Anticipatory” Drug-Seeking for Ethanol</b>	
C. Chiamulera, M. Tessari, and E. Valerio.....	288
<b>Development and Validation of a New Questionnaire to Assess Craving for Alcohol</b>	
E. G. Singleton, S. T. Tiffany, and J. E. Henningfield .....	289
<b>Screening the Plasma of Light and Heavier Social Drinkers for Potential Biochemical Markers of Cue-Induced Craving for Alcohol</b>	
C. C. Ryan, J. D. Greeley, A. J. Nimmo, Y. M. Tan, and J. M. Carstairs.....	290
<b>Cardiotoxicity in Asymptomatic Female Alcoholic Inpatients</b>	
N. C. Bernardy, A. J. Boquet, S. J. Nixon, and W. R. Lovallo.....	291
<b>The Relationship Between Spiritual Experience and Alcohol Use</b>	
M. M. Arias, T. E. Douglas, E. G. Singleton, and J. D. Kass.....	292
<b>Predictors of Outcome for Persons Completing Inpatient Treatment for Alcohol Dependence</b>	
D. Presti, S. L. Tunis, M. Young, and K. L. Delucchi .....	293
<b>Risk and Protective Factors in Alcohol Use Among African American College Students</b>	
A. Rhodes and E. G. Singleton.....	294
<b>Conduct Disorder and Relative Risk of Violence, Emotional Problems, and Alcohol and Other Drug Use in Adolescent Females</b>	
G. Dale and E. G. Singleton.....	294
<b>Personality Disorders, Alcohol Use, and Familial Risk Status in College-Age Men</b>	
J. D. Bedrick and A. I. Alterman .....	295
<b>Drug Dependence and Obsessive Compulsive Personality (OCP)</b>	
M. K. Romach, H. L. Kaplan, G. Somer, and E. M. Sellers.....	296
<b>Sex Differences in Twin-Pair Closeness and Concordance for Alcoholism</b>	
M. C. Labuda and R. W. Pickens .....	297
 <i><b>Marijuana</b></i>	
<b>Effects of Familial Alcoholism on Female Marijuana Users</b>	
B. W. Lex, S. K. Teoh, J. H. Mendelson, K. Kissell, and S. Peters.....	298
<b>The Effects of Marijuana History on the Reinforcing, Subjective and Behavioral Effects of Nitrous Oxide in Humans</b>	
S. Yajnik, J. P. Zacny, P. Thapar, T. Patterson, and J. L. Lichtor.....	299



<b>Does Smoking Marijuana Cause Reversible Retinal Vascular Changes?</b> I. K. Abukhalaf, P. M. Kemp, B. R. Manno, J. E. Manno, D. D. Alford, and T. W. Tubre.....	300
<b>Structural Characterization of Cannabinoid Receptor Genes</b> A. Chakrabarti, E. S. Onaivi, and G. Chaudhuri.....	301
<i>Cocaine: Pharmacology and Pharmacotherapy</i>	
<b>Double-Blind Trials with Oral Cocaine as Coca Tablets (CTA), Used for Cocaine Dependence Treatment</b> T. Llosa.....	302
<b>Diethylpropion Therapy for Inpatient Treatment of Cocaine Dependence</b> S. I. Deutsch, T. N. Alim, R. B. Rosse, T. Lindquist, and F. Vocci, Jr. ....	303
<b>Safety and Efficacy of Bupropion in Combination with Bromocriptine for Treatment of Cocaine Dependence</b> I. D. Montoya, K. L. Preston, R. Rothman, E. Cone, and D. A. Gorelick .....	304
<b>Imipramine for the Treatment of Cocaine and Methamphetamine Dependence</b> G. P. Galloway, J. Newmeyer, T. Knapp-Duncan, S. A. Stalcup, and D. Smith.....	305
<b>Comparison of Placebo and Dual Treatment Agents for Cocaine and Methamphetamine Detoxification</b> F. Tennant.....	306
<b>Combined Use of Fenfluramine and Phentermine in the Treatment of Cocaine Addiction: A Pilot Case Series</b> R. B. Rothman, T. Gendron, L. E. Thompson, Jr. III, and P. Hitzig.....	307
<b>Tyrosine for Treatment of Cocaine Dependence: A Historically Controlled Trial</b> F. E. Stagers, G. P. Galloway, G. Hayner, W. O. Wiehl, E. Sajo, D. Amodia, J. A. Schwedes, S. L. Frederick, and P. Stewart.....	308
<b>Desipramine and Counseling for Treatment of Cocaine Dependence: A Controlled Study</b> L. Covi, J. M. Hess, N. A. Kreiter, and I. D. Montoya .....	309
<b>Fluoxetine Effects on Cocaine Response: A Double-Blind Assessment</b> S. L. Walsh, J. T. Sullivan, and G. E. Bigelow	310
<b>Interaction of Selegiline and Cocaine in Human Cocaine Abusers</b> K. A. Haberny, S. L. Walsh, D. Ginn, I. A. Liebson, and G. E. Bigelow .....	311

<b>An Analysis of Factors Influencing Subject Participation in a Trial of Carbamazepine for Cocaine-Dependence Treatment</b>	
J. W. Cornish, I. Maany, P. J. Fudala, S. A. Poole, and C. P. O'Brien .....	312
<b>A Quantitative Assessment of Urinary Benzoyllecgonine Levels as Indicators of Carbamazepine Efficacy for Cocaine-Dependence Treatment</b>	
I. Maany, J. W. Cornish, P. J. Fudala, S. A. Poole, and C. P. O'Brien .....	313
<b>Nimodipine Pharmacotherapeutic Adjuvant Therapy for Inpatient Treatment of Cocaine Dependence</b>	
R. B. Rosse, T. N. Alim, T. Lindquist, and S. I. Deutsch .....	314
<b>Subacute Cardiovascular Effects of IV Cocaine in Humans with 24 Hour Holter and BP Recordings</b>	
L. L. Weinhold, R. A. Nelson, W. R. Lange, and D. A. Gorelick .....	315
<b>Risk Factors for Adverse Cardiovascular Events in Cocaine-Dependent Research Subjects</b>	
D. L. Frankenfield, D. A. Gorelick, L. L. Weinhold, C. S. Contoreggi, and W. R. Lange .....	316
<b>Cardiovascular Effects of Cocaine Use in Outpatients Taking Anti-Depressant Medication</b>	
R. A. Nelson, R. M. Keenan, D. A. Gorelick, G. N. Carmona, N. J. Carriero, and L. Covi .....	317
<b>Rapid Arterial Kinetics of Intravenous and Smoked Cocaine: Relationship to Subjective and Cardiovascular Effects</b>	
S. M. Evans, E. J. Cone, and J. E. Henningfield .....	318
<b>Effects of Carbamazepine on EEG Activity and Mood in Cocaine-Dependent Outpatients</b>	
L. O. Bauer and H. R. Kranzler .....	319
<b>Replication of Quantitative EEG Deviations in Cocaine Abstinent Subjects</b>	
R. A. Roemer, A. Cornwell, D. B. Dewart, and P. Jackson .....	320
<b>Cognitive Function in Abstinent Crack-Cocaine Users</b>	
C. Ollo, T. N. Alim, and S. I. Deutsch .....	321
<b>Evaluation of Cocaine Withdrawal Using the Cocaine Selective Severity Assessment</b>	
K. Kampman, D. McGinnis, A. Alterman, J. Volpicelli, R. Weinrieb, L. Epperson, and L. D'Angelo .....	322
<b>Growth Hormone Responses to Dopamine Antagonists in Cocaine Addicts and Alcoholics</b>	
C. K. Farren, C. McDougle, L. Price, D. Ziedonis, F. Hameedi, and T. Kosten .....	323

<b>Dopaminergic Responsivity and Prolactin Levels in Cocaine and Heroin Dependent Men: A Pilot Study</b>	
S. K. Teoh, J. H. Mendelson, N. K. Mello, S. Springer, M. Eros-Samyai, L. Goldstein, A. Skupny, and J. W. Sholar.....	324
<b>Serotonergic Function During Acute and Chronic Cocaine Abstinence</b>	
F. A. Hameedi, M. I. Rosen, L. H. Price, C. K. Farren, S. W. Woods, and T. R. Kosten.....	325
<b>Plasma Butyrylcholinesterase Activity in Substance Abusers</b>	
C. Washington, R. Woosley, K. Dretchen, A. Singh, I. Montoya, N. Carriero, and D. Gorelick.....	326
<b>Self-Reported Drug Use Compared with Hair Analysis and Urinalysis</b>	
J. A. Hoffman, E. D. Wish, J. J. Koman, III, S. J. Schneider, P. M. Flynn, and J. W. Luckey.....	327
<b>Hair Analysis - A Method of Validation for Self-Report of Cocaine Use</b>	
S. Chaudhari, F. Ursitti, J. Klein, G. Koren, and E. Sellers.....	328
<b>The Utility of Quantitative Urinalysis for Benzoylgonine in Clinical Trials for the Assessment of Cocaine Use</b>	
S. -H. Li, C. N. Chiang, B. Tai, C. Marschke, and R. Hawks .....	329
<b>Quantitative Measurement of Urine Benzoylgonine: Is it a Useful Measure of Cocaine Abuse?</b>	
S. L. Batki, K. Delucci, P. Jacob, III, A. M. Washburn, L. B. Manfredi, and R. T. Jones.....	330
<b>Quantitative Measurement of Benzoylgonine as a Marker for Relapse to Cocaine Abuse</b>	
K. Reid, J. E. Peters, J. Chou, A. Ho, L. Borg, and M. J. Kreek.....	331
<b>Cocaine and Methamphetamine Addicts Relapse when Urine Metabolite Concentrations Drop Below a Critical Level</b>	
D. Moll and F. Tennant.....	332
<b>Gender Differences in Cerebral Perfusion in Cocaine Abuse: TC-99M HMPAO SPECT Study of Drug Abusing Women</b>	
J. M. Levin, B. L. Holman, J. H. Mendelson, S. K. Teoh, B. Garada, K. Johnson, and S. Springer.....	333
<b>Application of Abbott ADX/TD -Based Procedures to Yield Semi-quantitative Urine Results in a NIDA Pharmacologic Trial</b>	
J. Wilkins, D. Setoda, S. -H. Li, and P. Bridge.....	334
<b>One Year Follow-Up to Cocaine Treatment Research Protocols</b>	
J. M. Hess, N. A. Kreiter, L. Covi, and K. L. Preston.....	335
<b>Gender Differences and Similarities in African-American Crack Cocaine Abusers</b>	
A. Lundy, E. Gottheil, R. D. Serota, S. P. Weinstein, and R. C. Sterling .....	336

<b>Stress, Coping and Social Support Among African-American Women in Treatment or “Crack” Cocaine Addiction</b>	
K. Robinson, A. Henry, G. Hughes, and P. E. Evans.....	337
<b>Antisocial Personality Disorder in Women: Problems and Issues</b>	
M. J. Rutherford, J. S. Cacciola, and A. I. Alterman.....	338
<b>Smoked Cocaine Self-Administration in Females</b>	
S. Dudish and D. Hatsukami.....	339
<b>Assessment of the Frequency and Enjoyability of Pleasant Events in Cocaine-Dependent Patients</b>	
M. L. Van Etten, S. T. Higgins, A. J. Budney, J. R. Hughes, and W. K. Bickel.....	340
<b>Temporal Patterns of Cocaine Use</b>	
M. Palij, A. Rosenblum, S. Magura, M. Lovejoy, J. Foote, L. Handelsman, and B. Stimmel.....	341
<b>The Context for Taking Cocaine Versus for Overcoming the Urge to take Cocaine</b>	
D. Mercer, L. Luborsky, J. McKay, S. Johnson, K. Schmidt, A. T. McLellan, and J. Barber.....	342
<b>Factors Associated with Successful Follow-Up Contact of Crack Cocaine Users</b>	
R. C. Sterling, E. Gottheil, S. P. Weinstein, A. Lundy, and R. D. Serota.....	343
<b>Cocaine and Sexuality Questionnaire: Preliminary Findings</b>	
D. W. Mayo, J. A. Hoffman, J. J. Koman, III, and B. D. Caudill.....	344
<b>Screening Treatment-Seeking Cocaine Addicts for PTSD</b>	
E. Triffleman, S. Ball, and B. Rounsaville.....	345
<b>Cognitive-Behavioral Cocaine Treatment With and Without Contingency Management</b>	
K. C. Kirby, D. B. Marlowe, R. J. Lamb, S. D. Husband, and J. J. Platt.....	346
<b>Family History of Substance Abuse in Cocaine Abusers</b>	
W. M. Compton, L. B. Cottler, and A. Ben-Abdullah.....	347
<b>Correlates of Cocaine Use Reduction</b>	
A. Paredes, E. Khalsa, and D. Anglin.....	348
<b>The Process of Development of a Counseling Manual for Controlled Treatment Studies of Cocaine Abuse</b>	
N. A. Kreiter, L. Covi, J. M. Hess, and M. Arias.....	349
<b>Relapse Prevention Treatment in Recently Hospitalized Cocaine Dependent Patients</b>	
J. M. Schmitz, L. M. Oswald, H. Rhodes, R. Elk, and J. Grabowski .....	350

<b>Treatment Intensity and Outcome With Homeless Cocaine Abusers</b> J. E. Schumacher, J. B. Milby, J. M. Raczynski, E. Caldwell, M. Engle, J. Carr, and M. Michael .....	351
<b>Effect of Drug of Choice, Family Involvement, and Employer Involvement on Treatment Completion Rates of Substance Abusers</b> D. Carise, R. Forman, and M. Randall.....	352
<b>Social Support and Treatment Outcomes Among Crack Users</b> B. D. Caudill, J. W. Luckey, P. M. Flynn, J. A. Hoffman, J. J. Koman, III, and A. C. Theisen.....	353
<b>Community Outcomes Following Research Exposure to Cocaine or Opioids</b> G. E. Bigelow, R. K. Brooner, S. L. Walsh, K. L. Preston, and I. A. Liebson.....	354
 <i>Cocaine: New Analogs</i>	
<b>The Discovery of a Novel Tropane Analog Which Binds Potently and Selectively to the Dopamine Transporter</b> P. C. Meltzer, A. Y. Liang, and B. K. Madras.....	355
<b>In Contrast to R-Cocaine Congeners, Novel Benztropine Analogs of Cocaine are Active in the S-Form: Implications for Cocaine Binding</b> B. K. Madras, A. Y. Liang, and P. C. Meltzer.....	356
<b>PET Imaging of Cocaine Binding Sites on the Dopamine Transporter: An Application for Medications Development</b> A. L. Brownell, B. K. Madras, D. E. Elmaleh, and P. C. Meltzer.....	357
<b>Modulation of Cocaine-Induced Increases in Nucleus Accumbens Dopamine Levels by Kappa Opioid Ligands</b> I. M. Maisonneuve and S. D. Glick.....	358
<b>Preliminary Characterization of Multiple Non-Serotonergic [<sup>125</sup>I]RTI-55 Binding Sites in Membranes Prepared from Whole Rat Brain Minus Caudate</b> M. L. Silverthorn, C. M. Dersch, J. S. Partilla, D. Matecka, K. C. Rice, F. I. Carroll, and R. B. Rothman .....	359
<b>A Comparative Study of [<sup>125</sup>I]RTI-55 Binding to the DA Transporters of Rat-, Monkey-, and Human-Caudate Membranes and the Cloned Rat and Human DA Transporters Expressed in COS and CHO Cells</b> C. M. Dersch, M. L. Silverthorn, J. S. Partilla, G. R. Uhl, J. -B. Wang, D. Vandenberg, J. L. Cadet, J. R. Glowa, F. I. Carroll, and R. B. Rothman.....	360
<b>Further Investigation of Structure- Activity Relationship of New GBR12935 and GBR12909 Analogs as Potent Dopamine Reuptake Inhibitors</b> D. Matecka, B. R. de Costa, R. B. Rothman, C. M. Dersch, J. Partilla, M. L. Silverthorn, A. Pert, J. Glowa, F. Wojnicki, A. Jacobson, and K. C. Rice .....	361

<b>Relationship Between Cocaine-Induced Changes in Dopamine Clearance and Striatal <i>In Vivo</i> Electrochemical Electrode Localization</b>	
E. J. Cline, C. E. Adams, G. A. Larson, G. A. Gerhardt and N. R. Zahniser.....	362
<b>[<sup>3</sup>H]-7-OH-DPAT Binds Dopamine D<sub>3</sub> and Sigma<sub>1</sub> Receptors in the Rat Nucleus Accumbens</b>	
R. M. Booze and D. R. Wallace.....	363
<b>Localization of Dopamine Receptor Subtypes Occupied by Intra-Accumbens Antagonists that Reverse Cocaine-Induced Locomotion</b>	
J. L. Neisewander, L. E. O'Dell, and J. C. Redmond.....	364
 <i>Cocaine: Behavioral Pharmacology</i>	
<b>Role of Corticosterone in the Modulation of DA and NE Overflow in the Awake, Freely-Moving Rat: Implications for the Mechanism of Action of Cocaine</b>	
D. N. Thomas, R. M. Post, and A. Pert.....	365
<b>Self-Administration of Dopamine Agonists: Comparison with Cocaine</b>	
D. M. Grech, R. D. Spealman, and J. Bergman.....	366
<b>Characterization of the Behavioral Effects of (±)-7-Hydroxy-Dipropylaminotetralin (7-OH-DPAT)</b>	
B. Geter-Douglass, K. L. Alling, J. B. Acri, J. M. Witkin, and J. L. Katz.....	367
<b>The Reinforcing Effects of the Putative Dopamine D-3 Agonist 7-OH-DPAT in Rhesus Monkeys</b>	
M. A. Nader.....	368
<b>Effects of Dopamine Reuptake Inhibitors on FR Responding Maintained by Cocaine and Food</b>	
J. R. Glowa, F. H. Wojnicki, D. Matecka, K. C. Rice, and R. B. Rothman.....	369
<b>Effects of Monoamine Uptake Inhibitors on Cocaine Self-Administration in Rats</b>	
S. R. Tella.....	370
<b>Studies on the Reinforcing Effects of GBR 12909 in Rhesus Monkeys</b>	
F. H. E. Wojnicki, D. Matecka, K. C. Rice, R. B. Rothman, and J. R. Glowa.....	371
<b>A Novel Progressive-Ratio Procedure for Studying Drugs as Reinforcers: Comparison Between Cocaine and Procaine in Rhesus Monkeys</b>	
W. L. Woolverton and M. Layng.....	372
<b>Cross-Tolerance Between Cocaine and CNS Stimulants Under a Progressive Ratio Paradigm</b>	
D. -H. Li and M. W. Emmett-Oglesby.....	373
<b>Amperozide Decreases Cocaine Self-Administration by Rats</b>	
D. C. S. Roberts and M. Andrews.....	374

<b>Maintenance of Self-Injection by Histamine H1 Antagonists in Baboons</b> C. A. Sannerud, B. J. Kaminski, and R. R. Griffiths .....	375
<b>The Effects of Cocaine, Alcohol and Cocaine/Alcohol Combinations on Schedule-Controlled Responding in the Rat</b> B. -F. X. Sobel and A. L. Riley.....	376
<b>Effects of Food Deprivation in a Model of Cocaine Relapse in Rats</b> S. D. Comer, S. T. Lac, and M. E. Carroll.....	377
<b>Acquisition of Cocaine Self-Administration in Rats: Correlation of Acquisition with Short Inter-Reinforcement Times</b> C. W. Schindler, R. W. Pickens, E. B. Thorndike, and S. R. Goldberg.....	378
<b>Reinforcing and Discriminative Stimulus Effects of <math>\beta</math>-CIT in Rhesus Monkeys</b> M. R. Weed, A. S. Mackevicius, J. Keababian, and W. L. Woolverton.....	379
<b>Effects of Sigma Ligands on the Cocaine Discriminative Stimulus in Rats</b> C. Cohen and D. J. Sanger .....	380
<b>Noradrenergic Mechanisms in the Discriminative Stimulus Effects of Cocaine: Influence of Training Dose</b> R. D. Spelman.....	381
<b>Evaluation of Cocaine Analogs More Selective for Dopamine Uptake in Rats and Squirrel Monkeys Trained to Discriminate Cocaine from Saline</b> P. M. Beardsley and R. L. Balster .....	382
<b>Analysis of the Effects of Diverse Antidepressants on the Discriminative Stimulus Effects of Cocaine</b> P. M. Callahan and K. A. Cunningham.....	383
<b>Effects of Exteroceptive Stimulus Conditions on Cocaine (COC) Discrimination in Discriminated Taste Conditioning (DTC)</b> B. L. Slifer and S. L. Serdikoff .....	384
<b>Behavioral Sensitization: Role of the Cyclic AMP System in Nucleus Accumbens</b> M. J. D. Miserendino and E. J. Nestler .....	385
<b>Intra-A10 Administration of the Protein Kinase C Inhibitor H7 Blocks the Development of Sensitization to Cocaine</b> J. D. Steketee .....	386
<b>A Single Injection of a Selective D-1 Agonist Into the Nucleus Accumbens Produces Sensitization to the Locomotor Activating Effects of Cocaine</b> T. J. De Vries and T. S. Shippenberg.....	387
<b>Sensitization and Conditioning with Intrastratial Administration of Dopamine Agonists</b> P. B. Silverman .....	388

<b>Sensitization to the Conditioned Rewarding Effects of Cocaine</b>	
C. H. Heidbreder and T. S. Shippenberg.....	389
<b>Chronic Cocaine Administration Does Not Produce Sensitization to the Locomotor Effects of GBR12909</b>	
A. Brockington, G. I. Elmer, D. A. Gorelick, F. I. Carroll, K. C. Rice, D. Matecka, S. R. Goldberg, and R. B. Rothman.....	390
<b><i>Cocaine: General Pharmacology</i></b>	
<b>Method for Analysis of Ibogaine in Plasma</b>	
A. R. Jeffcoat, B. F. Thomas, F. R. Ley, and C. E. Cook.....	391
<b>Evidence that Ibogaine Modulates Dopamine Release via a Kappa Receptor Mechanism</b>	
M. S. Reid, K. Hsu, P. Broderick, and S. P. Berger.....	392
<b>Ibogaine, the Putative Anti-addictive Drug is a Competitive Inhibitor of [<sup>3</sup>H]MK-801 Binding to the NMDA Receptor Complex</b>	
P. Popik, R. T. Layer, and P. Skolnick.....	393
<b>Acute Ibogaine and Cocaine: Actions and Interactions in Rhesus Monkeys</b>	
M. D. Aceto, E. R. Bowman, and Z. Ji.....	394
<b>Haloperidol Prevents Cocaine-Induced Rausch in Rhesus Monkeys</b>	
E. R. Bowman, Z. Ji, and M. D. Aceto.....	395
<b>Cocaine Abstinence Phenomenon: Differentiation of Withdrawal Phases in Rodents</b>	
A. Hitri, M. Stambuk, and S. I. Deutsch.....	396
<b>Analysis of 5HT 1A Autoreceptor Function After Chronic Cocaine Exposure in Rats</b>	
M. H. Baumann, H. Wimbrow, and R. B. Rothman .....	397
<b>Differential Effects of (+)-HA960, A Glycine-Site Partial Agonist on Cocaine-Induced Locomotor Activation</b>	
M. Shoaib, S. R. Goldberg, and T. S. Shippenberg.....	398
<b>Chromosomal Mapping of Loci Influencing Cocaine Sensitivity in BXD Recombinant Inbred Mice</b>	
L. L. Miner and R. J. Marley.....	399
<b>Detection and Chromosome Mapping of Quantitative Trait Loci Associated with Cocaine Responses in Inbred Mice</b>	
B. K. Tolliver, J. K. Belknap, and J. M. Carney.....	400
<b>The Expression of Protein Kinase C Isoforms in PC-12 Cells Are Differentially Modulated by Alcohol and Cocaine</b>	
C. Bishop-Robinson, L. Freeman, Y. D. Mock, B. D. Ford, E. D. Motley, K. A. Parker, A. Chakrabarti, G. Chaudhuri, S. S. Chirwa, and E. S. Onaivi.....	401



<b>Evidence for Noradrenergic Mechanisms in Cocaine-Induced Suppression of Renin Secretion</b>	
L. D. Van de Kar, K. Kunimoto, Q. Li, A. D. Levy, and J. M. Yracheta .....	402
<b>Behavioral and Histopathological Effects of Chronic Cocaine Administration</b>	
T. -A. Ansah, W. C. Udoji, and D. C. Shockley .....	403
<b>Effects of Phentermine and Fenfluramine on Extracellular Dopamine and Serotonin in Rat Nucleus Accumbens</b>	
M. A. Ayestas, M. H. Baumann, and R. B. Rothman.....	404
 <i>Amphetamines</i>	
<b>Is Protein Kinase C Activation a Key Step in MDMD-Induced Neurotoxicity of Serotonergic Neurons?</b>	
H. K. Kramer and E. C. Azmitia.....	405
<b>Methcathinone: A New Amphetamine-Like Drug of Abuse</b>	
J. M. Tolliver.....	406
<b>Mechanisms Involved in Methamphetamine-Induced Tolerance</b>	
M. P. Gygi, S. P. Gygi, M. Johnson, D. G. Wilkins, J. W. Gibb, and G. R. Hanson .....	407
<b>Methylenedioxymethamphetamine (MDMA)-Induced Dopamine and Serotonin Release <i>In Vivo</i> Are Attenuated by Reserpine Pretreatment</b>	
K. E. Sabol, J. B. Richards, and L. S. Seiden.....	408
<b>Transitions in Routes of Administration of Regular Amphetamine Users</b>	
S. Darke, J. Cohen, J. Ross, J. Hando, and W. Hall.....	409
<b>Methcathinone - A Potent New Drug of Abuse</b>	
W. L. Pickard, D. E. Presti, D. Harlow, and G. Galloway.....	410
 <i>Anabolic Steroids</i>	
<b>The Effects of Acute Cocaine Administration in Anabolic-Androgenic Steroid Abusers</b>	
M. B. Sholar, S. E. Lukas, M. Fortin, J. Wines, Jr., H. G. Pope, Jr., G. Cheng, L. Fortin, and J. H. Mendelson.....	411
<b>Abused Anabolic Steroids Rapidly Induce Anxiolytic Behavioral Changes in Mice</b>	
R. E. Osborne, I. Niekrasz, and T. W. Seale.....	412
<b>Behavioral Effects of Anabolic Steroids: Alteration of the Motor Responses of Mice to Either Pentobarbital or Cocaine</b>	
D. R. Compton .....	413

*Hallucinogens, Sigma Receptors, and Inhalants*

**Raves, Youth and Drugs**

- D. Harlow, M. Kleiman, R. Jesse, W. L. Pickard, and  
D. McDowell ..... 414

**Phencyclidine Pharmacokinetics in Neonatal Piglets**

- F. M. Scalzo, L. J. Burge, J. Valentine, R. Karba, and  
S. Primozić ..... 415

**Effects of Postnatal Phencyclidine Exposure on NMDA Receptor  
Distribution Pattern**

- R. Sircar and J. -J. He ..... 416

**Evaluation of the Reinforcing and Discriminative Stimulus Effects of  
Dextromethorphan and Dextrorphan in Rhesus Monkeys**

- K. L. Nicholson, B. A. Hayes, and R. L. Balster ..... 417

**Discriminative Stimulus Effects of Dextromethorphan**

- S. G. Holtzman ..... 418

**Sigma Receptor-Mediated Morphological and Cytotoxic Effects on  
Primary Cultures of Neurons**

- B. J. Vilner and W. D. Bowen ..... 419

**Preparation of an Affinity Column for the Purification of Sigma  
Receptors**

- L. -I. Tsao and T. -P. Su ..... 420

**Differential Solubilization of Sigma-1 and Sigma-2 Receptors from  
Rat Liver Membranes**

- C. Torrence-Campbell and W. D. Bowen ..... 421

**Synthesis and Evaluation of Aryl-Substituted N-(Aryl-Ethyl)-N-  
Methyl-2-(1-Pyrrolidinyl)Ethylamines for Sigma Receptor Affinity**

- Y. Zhang, W. D. Bowen, W. Williams, X. S. He, B. R. de Costa,  
and K. C. Rice ..... 422

**Introduction of an E-8-Benzylidene Moiety in the 2-Methy-5-Phenyl-  
Morphan System Abolishes Opioid Effects and Affords a New Class  
of Potent Sigma Receptor Ligands**

- C. M. Bertha, M. V. Mattson, J. L. Flippen-Anderson, R. B. Rothman,  
H. Xu, X. -Y. Cha, K. Becketts, and K. C. Rice ..... 423

**Murine Peritoneal Macrophage Tumoricidal Activity is Inhibited by  
Inhaled Isobutyl Nitrite**

- L. S. F. Soderberg and J. B. Barnett ..... 424

**Abuse Potential Evaluation of Volatile Solvents: A First Attempt**

- R. L. Balster, E. B. Evans, M. E. Tokarz, J. Hamilton, and  
S. E. Bowen ..... 425

**The Effects of Abused Inhalants on Locomotor Activity in Mice**

- S. E. Bowen and R. L. Balster ..... 426

<b>Effects of Different Doses of Naloxone on the Subjective and Psychomotor Effects of Nitrous Oxide in Humans</b>	
D. W. Coalson, J. P. Zacny, J. L. Lichtor, S. Yajnik and P. Thapar .....	427

*Commentary*

<b>Addiction Research in Historical Perspective</b>	
C. J. Acker .....	428

<b>Reporting and Representation of Sociodemographic Groups in Cocaine Pharmacotherapy Studies</b>	
D. A. Gorelick and I. D. Montoya.....	429

<b>Ethnic and Gender Factors in Addiction Research</b>	
J. M. Beal, E. G. Singleton, and J. E. Henningfield .....	430

<b>ACT UP/New York’s Needle Exchange Program</b>	
G. Elbaz .....	431

<b>Activists and Service Provision: An Analysis of an Illegal Needle Exchange</b>	
K. D. Henson .....	432

<b>Adult Attention Deficits Disorder and Substance Abuse: A Selective Review of MMPI Findings</b>	
A. M. Horton, Jr .....	433

<b>Kappa Fails to Correct for Chance Agreement when Drug Use Self-Reports are Validated by a Single Urine Sample</b>	
S. J. Robbins and R. N. Ehrman.....	434

<b>Cocaine Addiction as a Neurological Disorder</b>	
M. D. Majewska .....	435

<b>Rapid Computerized Determination of Pupil Diameter from Imperfect Video Images</b>	
H. L. Kaplan .....	436

<b>Comparison of Statistical Methods for Analyzing Repeated Measures Data</b>	
L. J. Felch, M. E. Di Marino, and K. C. Kirby.....	

**Oral Communications**

*Infectious Diseases Complicating Addictions*

<b>Tuberculosis Knowledge Among New York City (NYC) Injecting Drug Users (IDUs) and Sexual Partners of IDUs</b>	
M. Marmor, H. Wolfe, D. Des Jarlais, and A. Moss.....	438

<b>Hepatitis C Virus Serology in Parenteral Drug Users With Chronic Liver Disease</b>	
D. M. Novick, K. J. Reagan, T. S. Croxson, A. M. Gelb, R. J. Stenger, and M. J. Kreek .....	439

<b>Seroprevalence of Hepatitis A, B, C, and D Markers and Liver Function Abnormalities in Intravenous Heroin Addicts</b>	
J. Cassidy, F. Tennant, and D. Moll .....	440
<b>Mouse Strain is a Major Variable in <i>In Vitro</i> Immunosuppression by Opioids</b>	
T. K. Eisenstein, J. J. Meissler, Jr., M. W. Adler, E. B. Geller, and T. J. Rogers.....	441
<b>Morphine Suppresses Immune Responses to MNrgp120/HIV-1 in Mice: Potential Relevance for AIDS Vaccines</b>	
P. A. Virsik and J. L. Bussiere .....	442
<b>Medication Adherence Requirements for IDUs With HIV Disease</b>	
J. L. Sorensen, S. L. Batki, J. A. London, D. DePhilippis, A. Mascovich, and T. A. Wall.....	443
<b>Can We Identify What is Associated With the Stability of IDU Willingness to be in Preventive HIV Vaccine Efficacy Trials?</b>	
K. Meyers, D. S. Metzger, A. T. McLellan, H. Navaline, and G. E. Woody.....	444
<b>Relationship of Drug Abuse and HIV Serostatus to Neuropsychological Functioning in Minority Men</b>	
M. Quiroga, M. J. Selby, S. J. Ireland, and R. Malow .....	445
 <i>Analgesia</i>	
<b>Relative Analgesic Potency of Mu and Kappa Opioids in Amphibians: A Unique Assay for Kappa Opioid Action?</b>	
C. W. Stevens, A. J. Klopp, and J. A. Facello.....	446
<b>Unique Effects of the d<sub>2</sub>-Opioid Agonist Deltorphin II with d<sub>1</sub> and μ-Agonists in Inbred Mouse Strains</b>	
G. I. Elmer, J. Evans, and J. H. Woods .....	447
<b>Exposure to Volatilized Opioids Produces Antinociception in Mice</b>	
A. H. Lichtman and B. R. Martin.....	448
<b>Irreversible Mu Opioid Antagonist Clocinnamox Reveals Etonitazene to be High-Affinity, Low-Efficacy Agonist</b>	
G. Zernig, J. W. Lewis, and J. H. Woods.....	449
<b>Apparent Affinity Estimates for Opioid Antagonists in Rats Treated With Clocinnamox or Chronic Morphine</b>	
E. A. Walker, T. M. Richardson, and A. M. Young.....	450
<b>Diurnal Cycle and Flavor Effects on Opioid Antinociception in Infant Rats</b>	
K. F. Green, R. J. Beitner, C. E. Schlundt, and S. O. Werner .....	451
<b>The Role of Serotonin in the Antinociceptive Effects of Mu and Kappa Opioids</b>	
K. R. Powell and L. A. Dykstra.....	452

<b>Behavioral Effects of the Delta Opioid Agonist BW373U86 in Rhesus Monkeys</b>	
E. R. Butelman, M. B. Gatch, S. S. Negus, G. Winger, and J. H. Woods .....	453
<b>Subanesthetic Doses of Nitrous Oxide Reduce Cold Pressor-Induced Pain in Humans</b>	
V. Pirec, J. P. Zacny, P. Thapar, and J. L. Lichtor .....	454
 <i>Cocaine Interactions</i>	
<b>Cardiorespiratory Effects of Cocaine-Heroin Combinations in the Anesthetized Rabbit</b>	
H. K. Erzouki, S. R. Goldberg, and C. W. Schindler .....	455
<b>Kappa Opioid Receptor Agonists Prevent Sensitization to the Rewarding Effects of Cocaine</b>	
T. S. Shippenberg and C. H. Heidbreder .....	456
<b>Effect of the Delta Opioid Antagonist Naltrindole on Cocaine Discrimination and Self-Administration in Rhesus Monkeys</b>	
S. S. Negus, N. K. Mello, P. S. Portoghese, S. E. Lukas, and J. H. Mendelson.....	457
<b>Ethanol Co-treatment Increases Blood and Brain Cocaine Levels in Mice</b>	
I. R. Tebbett, D. L. Phillips, R. D. Harbison, and S. M. Roberts.....	458
<b>CNS Stimulants Produce Cross-Tolerance to Cocaine in an FR2 Schedule of Cocaine Self-Administration</b>	
R. L. Peltier and M. W. Emmett-Oglesby .....	459
<b>Modulation of Cocaine-Induced Sensitization by Nitric Oxide</b>	
Y. Itzhak, J. Winograd, and M. Norenberg.....	460
<b>Effects of a Nitric Oxide Synthase Inhibitor on the Discriminative Stimulus Effects of Cocaine and on Substitution Profiles of DA- and NMDA- Related Drugs</b>	
K. M. Kantak and M. A. Edwards.....	461
<b>The HPA Axis and Cocaine Self-Administration</b>	
N. E. Goeders and G. F. Guerin.....	462
<b>Effects of Cocaine and Corticotropin Releasing Factor (CRF) on Pulsatile ACTH and Cortisol Release in Ovariectomized Rhesus Monkeys</b>	
Z. Sarnyai, N. K. Mello, J. H. Mendelson, M. Eros-Sarnyai, P. Nguyen, M. Kelly, H. Gelles, and Y. G. Cheng.....	463
 <i>Opioids: Behavioral, Psychosocial and Other Treatment</i>	
<b>The Relationship of Counselor and Peer Alliance to Drug Use and HIV Risk Behaviors in a Six-Month Methadone Detoxification Program</b>	
S. L. Tunis, K. L. Delucchi, K. Schwartz, P. Banys, and K. Sees.....	464

<b>Effectiveness of Integrating Enhancements to Standard Methadone Treatment for Subjects at High Risk for HIV Transmission</b>	
S. Shoptow, R. Rawson, C. Grella, D. Anglin, and A. Hasson .....	465
<b>Acupuncture as an Adjunct to Services Provided at Methadone Treatment Facilities</b>	
T. R. Jackson, E. A. Wells, O. R. Diaz, V. Stanton, and A. J. Saxon .....	466
<b>Outcomes From Differing Levels of Intervention in a Methadone Maintenance Program</b>	
J. M. White and C. F. Ryan .....	467
<b>A Modified Therapeutic Community Method for Methadone-Maintained Clients: Effectiveness and Client Correlates of Outcome</b>	
G. De Leon, G. Staines, T. Perlis, and K. McKendrick .....	468
<b>Retention in Methadone Maintenance by Duration in Treatment and Reason for Discharge</b>	
K. J. Besteman, L. Greefield, A. De Smet, B. T. Yates, and J. Filipczak.....	469
<b>Drug Abuse Treatment of Narcotic and/or Cocaine Abusing Parolees</b>	
T. E. Hanlon, D. N. Nurco, R. W. Bateman, and T. W. Kinlock.....	470
<b>Medical Maintenance: A Five Year Experience</b>	
E. C. Senay, A. G. Barthwell, R. Marks, and P. Bokos.....	471
<b>The Role of Social Relationships in Addictive Behavior: An Examination of an In-Treatment and Out-of-Treatment Sample</b>	
L. R. Goehl, D. S. Metzger, H. Navaline, G. E. Woody, and A. R. Childress .....	472
<b>Vocational Enhancement: Overview of Findings of one Research Demonstration Project</b>	
P. H. Kleinman, R. B. Millman, M. L. Lesser, H. Robinson, P. Engelhart, C. Hsu, and I. Finkelstein .....	473
 <i>Perinatal Issues Related to Addictions</i>	
<b>Mother-Infant Interaction Between Cocaine Abusing Parents and Their Three and Six Month Old Infants</b>	
L. C. Mayes, R. Feldman, R. H. Granger, and R. Schottenfeld .....	474
<b>Birth Outcome Not Correlated With Late-Term Cocaine Exposure Within an Exposed Sample</b>	
P. R. Marques, A. S. Tippetts and D. G. Branch.....	475
<b>Caregiving Influences on the Development of Infants Born to Cocaine-Addicted Women</b>	
J. Howard, L. Beckwith, M. Espinosa, and R. Tyler .....	476
<b>Maternal Psychosocial Characteristics of Pregnant Cocaine -Dependent Women: Residents Vs. Patients</b>	
M. Comfort, K. Kaltenbach, and A. Smith.....	477

<b>Changes and Stability in Family Functioning in Perinatal Addicts</b> D. L. Haller, K. S. Ingersoll, K. S. Dawson, and S. H. Schnoll .....	478
<b>Drug Withdrawal During Pregnancy-Fetal Effects</b> M. A. E. Jarvis, J. S. Knisely, and S. H. Schnoll .....	479
<b>Perinatal Outcomes of Infants Born to Drug-Dependent Women Enrolled in a Multi-Modality Treatment Program</b> K. Kaltenbach, M. Comfort, and A. Smith.....	480
<b>The Relationship Between Addiction Severity and a Five Factor Model of Personality in Pregnant Cocaine Abusers</b> S. A. Ball and R. S. Schottenfeld .....	481
<b>Cost-Effectiveness of Comprehensive Care for Drug-Abusing Pregnant Women</b> J. H. Lee and D. Svikis .....	482
<b>Hospitalization of Children Born to Cocaine-Using Mothers</b> B. W. Forsyth, J. M. Leventhal, and K. Qi .....	483
 <i>Opioid Receptors</i>	
<b>Opioid Peptide and Receptor mRNA Levels in the Rat Brain Determined by TCA Precipitation of mRNA: cRNA Hybrids</b> R. Spangler, Y. Zhou, E. Unterwald, V. Yuferov, A. Ho, and M. J. Kreek .....	484
<b>Evaluation of a Series of N-Alkyl Benzomorphans in a Cell Line Expressing Transfected <math>\delta</math>-Opioid Receptors</b> M. E. Abood, R. C. Carter, E. L. May, and L. S. Harris .....	485
<b>New Receptor Selective Opioid Agonists and Antagonists, Derived From Synthetic Combinatorial Libraries</b> C. T. Dooley and R. A. Houghten .....	486
<b>A 14<math>\beta</math>-Nitrocinnamoyl Derivative of Dihydro-Codeinone and its Corresponding N-Cyclopropyl-Methyl Analogue Act as Short-Term Mu-Selective Agonists and Long-Term Mu-Selective Antagonists</b> J. M. Bidlack, K. P. Hill, A. Sebastian, and S. Archer .....	487
<b>The Effect of Aromatic Substitution on the Activity of Some Standard Antagonists and Partial Agonists</b> J. W. Lewis, S. M. Husbands, C. Smith, M. Myers, P. A. Bradley, A. S. Haynes, and P. T. Taylor.....	488
<b>Antinociceptive Profile of SNC 80, a Highly Selective, Non-Peptidic Delta Opioid Agonist</b> F. Porreca, E. J. Bilsky, R. N. Bernstein, P. Davis, S. N. Calderon, K. C. Rice, and R. B. Rothman .....	489

## *Treatment of Cocaine Addiction*

### **Gender and Menstrual Cycle Influences on Cocaine's Effects in Human Volunteers**

S. E. Lukas, M. B. Sholar, M. Fortin, J. Wines, Jr., and  
J. H. Mendelson..... 490

### **Altered Dopaminergic Synaptic Markers in Cocaine Psychosis and Sudden Death**

J. K. Staley, C. V. Wetli, A. J. Rutenber, W. Lee Hearn,  
and D. C. Mash..... 491

### **SPECT Imaging of the Dopamine Transporter in Cocaine Abstinence: Preliminary Studies Using [123-I]β-CIT**

S. E. Best, R. T. Malison, E. A. Wallace, S. S. Zoghbi,  
Y. Zea-Ponce, R. M. Baldwin, R. B. Innis, and T. R. Kosten..... 492

### **Lower Frequency of the Drug Metabolizing Cytochrome P450 2D6 (CYP2D6) Deficiency Phenotype in a Cocaine-Dependent Population**

S. V. Otton, K. Droll, J. Klein, G. Koren, S. Chaudhari,  
and E. M. Sellers ..... 493

### **Effectiveness of Desipramine in Treating Cocaine Dependence**

R. A. Rawson, S. Shoptaw, M. J. McCann, and  
S. Minsky..... 494

### **A Composite Score for Evaluating Treatment Response in Cocaine Pharmacotherapy Trials (TES)**

W. Ling, S. Shoptaw, R. A. Rawson, and C. J. Klett..... 495

### **Treatment for Homeless Cocaine Abusers: Retention, Process and Outcome**

J. B. Milby, J. E. Schumacher, J. M. Raczynski, M. Engle,  
E. Caldwell, M. Michael, and J. Carr..... 496

### **Active Coping Strategies for Cocaine Cue Reactivity: Treatment Outcome**

A. R. Childress, R. Ehrman, L. Goehl, and C. P. O'Brien ..... 497

### **One-Year Outcome Following Outpatient Behavioral Treatment for Cocaine Dependence**

S. T. Higgins, A. J. Budney, W. K. Bickel, and D. Ogden ..... 498

## *Cannabinoids: Chemistry and Biology*

### **Synthetic Studies Directed Towards 18F-Labeled CP-55,244: A Potential Ligand for Imaging Cannabinoid Receptors**

P. R. Fleming, Z. -Q. Gu, S. Richardson, S. Mirsadeghi,  
L. S. Melvin, M. R. Johnson, and K. C. Rice..... 499

### **Analogues of Arachidonic Acid as Potential Ligands for the Cannabinoid Receptor**

J. C. Pinto, D. L. Boring, F. Potie, K. C. Rice, M. R. Johnson,  
C. Cantrell, G. H. Wilken, and A. Howlett ..... 500



<b>Physiological and Behavioral Effects of Anandamide, and Endogenous Cannabinoid, in the Rat</b>	
E. A. Stein, S. A. Fuller, W. S. Edgmond, and W. G. Campbell .....	501
<b>Cardiovascular Effects of Anandamide in Anesthetized Rats</b>	
K. Varga and G. Kunos .....	502
<b>Anandamine and <math>\Delta^9</math>-THC-Induced Dilation of Rabbit Cerebral Arterioles is Blocked by Indomethacin</b>	
E. F. Ellis and S. F. Moore .....	503
<b>EEG Effects of WIN55221-2, a Structurally Novel Cannabinoidmimetic, in Rats</b>	
F. C. Tortella and S. J. Ward .....	504
<b>Development of a “Composite” Measure of Alpha Hyperfrontality for Use in THC Research</b>	
F. Struve, G. Patrick, and J. Leavitt .....	505
<b>Cannabinoid Metabolite Concentration in Human Urine Varies With Method of Sample Hydrolysis</b>	
P. M. Kemp, I. K. Abukhalaf, B. R. Manno, J. E. Manno, and D. D. Alford .....	506
 <i>Cocaine: Pharmacology and Neurochemistry</i>	
<b>Time Course of Cocaine-Induced Alterations in Opioid and Dopamine Receptors and Transporter Sites</b>	
E. M. Unterwald, J. M. Rubinfeld, and M. J. Kreek.....	507
<b>Dopamine Transporter mRNA Levels in the Rat Substantia Nigra and Ventral Tegmental Area Immediately Following and at Two Days and Ten Days After “Binge” Cocaine Administration</b>	
C.E. Maggos, R. Spangler, Y. Zhou, E. M. Unterwald, and M. J. Kreek.....	508
<b>Secondary Amine Analogs of 3B-(4'-Substituted Phenyl)Tropane-2B-Carboxylic Acid Esters and N-Norcocaine Exhibit Enhanced Affinity for Serotonin and Norepinephrine Transporters</b>	
F. I. Carroll, M. J. Kuhar, T. Kopajtic, E. Yang, P. Abraham, A. H. Lewin, and J. W. Boja .....	509
<b>Discovery of a Novel Chiral Benzazepine Derivative, RTI-4793-41, Whose Enantiomers Bind Potently and With Moderate Enantioselectivity to PCP Site 2 and Cloned DA Transporters</b>	
B. Emilien, C. B. Goodman, C. M. Dersch, J. S. Partilla, J. L. Cadet, D. Vandenberg, J. -B. Wang, G. R. Uhl, F. I. Carroll, B. Blough, K. P. Constable, and R. B. Rothman .....	510
<b>Partial Purification of Cocaine Receptors From Rat Brain</b>	
L. P. Raymon and M. E. Eldefrawi .....	511
<b>Behavioral and Pharmacological Differentiation of Direct and Indirect Dopamine Agonists and Among Dopamine Uptake Inhibitors</b>	
J. M. Witkin, E. Tirelli, and B. Geter-Douglass.....	512

<b>Differential Relationships Among Dopamine Transporter Affinities and Stimulant Potencies of Various Uptake Inhibitors</b> S. Izenwasser; P. Terry; B. Heller; J. M. Witkin; and J. L. Katz .....	513
<b>Topography of Limbic Dopamine Uptake Sites in Human and Rat Brain</b> K. Y. Little, F. I. Carroll, and B. J. Cassin .....	514
<b>Cocaine Increases Extracellular Aspartate and Glutamate in Rat Nucleus Accumbens (N. ACC.)</b> S. E. Robinson; H. Guo; J. R. Maher; J. A. Smith; M. J. Wallace; D. T. Otey; and P. M. Kunko .....	515
<b>An Evaluation of the Novel Psychostimulant Drug, Modafinil, in Rhesus Monkey Self-Administration and Rat Drug Discrimination Paradigms</b> L. H. Gold and R. L. Balster .....	516
<b>Subject Index .....</b>	517
<b>Author Index .....</b>	536